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ABSTRACT 
Background: Pancreatic cancer (PC) is one of the most devastating cancers with less than 5% surviving 
after five years of diagnosis. Most of the risk factors have non-specific odds ratio except for chronic 
pancreatitis (CP) which has an extremely high odds ratio as reported in the literature. CP is characterized 
by inappropriate activation of trypsinogen in the pancreas resulting in inflammation of the pancreas. Most 
of the genetic factors behind the inflammatory to cancerous progression still remain unexplained. This 
research study describes identification of multiple non-synonymous mutations and implicates specific 
DNA repair pathways in the risk of progression from CP to PC. 
Methods: Whole exome sequencing was carried out in 16 CP individuals with PC and 11 individuals 
without PC, following which the thousand genomes project data was used to identify the rare and novel 
germline non-synonymous variants among 159 DNA repair genes and burden test of DNA repair 
pathways was used to identify the most frequently mutated DNA repair pathways. 
Results: We were able to able to identify at least 30 rare and novel non-synonymous germline variants at 
sufficient read depth in our CP+PC cohort that warrant investigation in pancreatic cancer tumor tissues as 
well as larger PC patient cohorts. 
Public Health Significance: The public health significance of this work lies in the fact that it provides for 
the first time an opportunity to genetically screen the potentially high risk pancreatic cancer patient 
cohorts to determine their individual risk of development of the disease and based on risk assessment, a 
strategy could be developed to determine if an individual needs to undergo high risk surgical procedures 
like total pancreatectomy to reduce their risk of developing pancreatic cancer or develop changes in their 
habits to reduce the possibility of the development of pancreatic cancer.   
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1.0 PANCREATIC CANCER 
 1.1 INTRODUCTION 
Pancreatic cancer (PC) is a highly malignant disease of the pancreas. It is usually highly metastasized by 
the time it is diagnosed. Thus it is associated with extremely poor quality of life and has very low one 
year and five year survival rates. The National Cancer Institute considers that pancreatic cancer is 
estimated to account for 45220 newly diagnosed cases of cancer out of total 1283788 estimated cancer 
cases in 2013 in USA which makes it the least frequent kind of major cancer among all the common 
cancers. (National Cancer Institute, 2013) However with an estimated death number at 38460, an 
alarming 85% are estimated to die within a year thus putting PC among the top brackets of disease 
specific mortality rates among all cancers.  
The most common mode of treatment is administration of gemcitabine, a nucleoside analogue 
that was found to have significant improvement in median overall survival as compared to fluoricil 
administration. However it increases survival by only 0.8 months (Di Marco M et al. 2010) and thus 
further genetic studies are warranted to identify suitable therapeutic targets to PC. Further subsequent 
phase 3 trials of gemcitabine as a single agent ranged only from 5 to 7.2 months and the combination of 
gemcitabine and other cytotoxic and targeted agents showed significant survival advantage as compared 
with gemcitabine alone but was also associated with increased toxicity. It was also concluded from this 
study that if response to drug was stable, then chemotherapy could be discontinued which often is known 
to have damaging side-effects in cancer individuals. (Conroy T et al. 2011)  Hence surgery remains the 
only other treatment option that offers an advantage in terms of 5 year overall survival.  Thus developing 
preventive measures against development of PC continues to be a top public health necessity.  
1.2 EPIDEMIOLOGY 
With an estimated 45220 new cases of PC in 2013, the incidence rate of pancreatic cancer is relatively 
low and would have been of little concern except for its high mortality rate. This high mortality rate 
places PC as the fourth or fifth most frequent cause of cancer death in most developed countries. (Ferlay J 
et al. 2010) 
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PC has a peculiar trend with respect to geographical variations in that the rates are 3 to 4 times 
higher in northern countries far away from the equator like Iceland, Finland or northern USA while 
countries close to the equator such as Egypt or India have much lower rates. Of the several reasons 
suggested for this phenomenon, the most common is believed to be related to age. Since the incidence of 
PC is strongly related to age, improving life span in the developed countries that will give to rise to 
increased population will give rise to increasing incidence of PC thus highlighting its public health 
importance. However, improvements in lifespan in the general population mean that the absolute 
frequency of pancreatic cancer is likely to rise in countries like China, India and other Asian regions that 
have large aging populations confirming its status as a disease of major public health concern. 
(Maisonneuve P et al. 2010) 
The following tables below shows the epidemiology data by NCI’s SEER Cancer Statistics Review. 
Table1.1: Median age of death and diagnosis stratified by race for PC in US for 2006-2010 
All races Whites Blacks 
Total Male Female Total Male Female Total Male Female 
PC median 
age of 
death 
73 70 75 73 71 76 69 66 72 
PC median 
age of 
diagnosis 
71 69 74 72 69 74 67 64 70 
Table 1.2: Incidence rate of PC stratified by sex and race for PC in US for 2006-2010 
Type of race Male 
(per 1,00,000) 
Female 
(per 1,00,000) 
All 13.9 10.9 
White 13.8 10.7 
Black 17.6 14.3 
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Table 1.3: Mortality rate of PC stratified by sex and race for PC in US for 2006-2010 
Type of race Male 
(per 1,00,000) 
Female 
(per 1,00,000) 
All 12.5 9.6 
White 12.5 9.4 
Black 15.3 12.5 
The above data displays the two grim aspects of reality with respect to PC. Table1 shows that PC 
is detected at a relatively late age with time from diagnosis and death being 2 years at the maximum and 
comparing table 2 and 3 data the incidence rate and mortality rate are very close implying current 
treatment measures in terms of surgery or drug is not effective for PC individuals. Thus developing 
effective methods for determining who is at risk of the disease and then devising methods for preventing 
development of those risk factors remains the most effective way to treat PC.  
 1.3 RISK FACTORS 
Pancreatic cancer is a highly heterogeneous disorder with the exact cause still unknown which possibly 
explains the difficulty of its clinical management and the high mortality rates. Several environmental 
factors have been implicated with causative evidence mainly for tobacco use with an association between 
smoking and pancreatic cancer showed by most published studies. (Iodice S et al. 2008).However most of 
them have relatively small odds ratio for PC that are not effective enough to be targeted for an 
intervention thus minimizing their role as putative screening factor for determining PC risk. Table 1.4 
includes a short list of factors with the risk that they are known to possess in PC.  
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Table 1.4 Major non-genetic risk factors of Pancreatic Cancer 
Risk factor Risk, CI* Reference 
Environment – lifestyle 
Smoking 1.74, CI 1.61-1.87 (Iodice S et al. 2008) 
Alcohol possible (Duell J et al. 2012) 
Occupational 
Chlorinated hydrocarbons 1.4-4.4 (Andreotti G et al. 2012) 
Polycyclic aromatic 
h d b  ( A )
1.5 (Andreotti G et al. 2012) 
Diet  
n-nitroso foods 1.27 CI 1.09-1.48 (Risch HA et al. 2012) 
saturated fat / animal fat ~1.2 – 2.0 (Sanchez GV et al. 2012) 
Medical conditions 
Pancreatitis 5.1     CI 3.5-7.3 (Raimondi S et al. 2012) 
Chronic pancreatitis 13.3   CI 6.1-28.9 (Raimondi S et al. 2012) 
Hereditary pancreatitis 69.9   CI 56.4-84.4 (Raimondi S et al. 2012) 
Allergies 0.39-0.77 (Olson SH 2012) 
Diabetes Mellitus 1.5-2.0 (Li D 2012) 
Obesity ~1.1-1.3 (Bracci PM 2012) 
ABO blood group 1.65 CI 1.30-2.09 (Risch HA et al. 2012) 
Despite the environmental risk factors in most cases having non-specific odds ratios, relatively 
rare medical conditions such as chronic pancreatitis and hereditary pancreatitis have been associated with 
the highest odds ratios of risk. The primary pathway between inflammation and cancer remains an area of 
active research and controversy. (Whitcomb DC 2004) It is hypothesized that the mechanism behind such 
elevated risk of PC in pre-existing cases of pancreatitis is related to the continuous exposure of duct cells 
to reactive oxygen species and other toxic inflammatory factors that can cause DNA damage and thus 
increased cell turnover (replacement of old cells with newly generated ones from existing ones) that 
facilitates clonal expansion of early metaplastic cells into metastatic PC. However with no more than 5% 
of diagnosed cases of pancreatic cancer being explained by recurrent attacks of chronic pancreatitis 
(Raimondi S et al. 2010) it is unclear which are the high risk CP individuals that are most likely to 
progress to PC. 
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1.4 CONUNDRUM-WHICH CP CASES WILL PROGRESS ON TO PC? 
The link between chronic inflammation and tumorigenesis has been recognized in several disorders 
including colorectal cancer after inflammatory bowel disease or bladder cancer after schistosomasis as 
well as pancreatic ductal adenocarcinoma after chronic pancreatitis. Severe inflammation during chronic 
inflammatory diseases exposes the tissues of the organ to the cytotoxic agents such as proinflammatory 
cytokines and reactive oxygen species. Their presence leads to activation of cellular protective 
mechanisms, such as cell death and acinar to ductal metaplasia and increased proliferation of replacement 
cells aimed at organ regeneration. Increased cell turnover in an environment rich in oxidative species 
favors accumulation of DNA damage thus increasing chances of positive selection for mutations that 
confer growth advantage.  
Thus of all the PC risk factors, CP and more specifically HP are by far the largest risk factors in 
terms of relative risk. A meta-analysis by Raimondi et. al. (Raimondi S et al. 2010) published in 2010 
showed that there was a statistically significant increase in the risk of pancreatic cancer risk for all the 
major type of pancreatitis, with summary RRs (95%CI) of 5.1 (3.5–7.3) for unspecified pancreatitis, 13.3 
(6.1–28.9) for chronic pancreatitis and 69.0 (56.4–84.4) for hereditary pancreatitis.      
Genetic studies addressing this issue have been few and in one of the earliest those studies by 
Moskovitz et. al. (Moskovitz et al. 2003) found an increased level of chromosomal abnormality in cell 
cultures of normal appearing, non-neoplastic pancreatic epithelia in both patients with chronic pancreatitis 
and patients with pancreatic cancer relative to normal donor-derived cells but there was no significant 
difference in chromosomal abnormalities in the ductal cells from patients with pancreatitis as compared to 
the cancer patients. Later Yan et. al. (Yan L et al. 2005) reported on the investigation of pancreatic juices 
from 146 patients with PDAC or CP or biliary tract stones and found that mutant p53 were present in a 
greater number of PC patients as compared to CP individuals and more recently in 2010, Baumgart et. al. 
(Baumgert M et al. 2010) reported that in the early PanIN of CP patients, there were heterozygous 
mutations of p53 and p16 along with chromosomal instability early in CP. With the vital role of the DNA 
repair system in maintaining the stability of the genome by preventing accumulation of mutations and 
thus preventing chromosomal instability, it could be argued that accumulation of mutations in DNA repair 
genes in a cancerous patient is interfering with their normal functioning that is preventing the repair of the 
DNA damage occurring in other critical cell cycle regulation genes and thus giving rise to loss of control 
of cell cycle regulation and a potential tumorigenic phenotype.  
Although these studies have looked at specific genes to be involved in the risk of PC in CP 
individuals, they have confirmed the role of genetic factors in the progression of chronic pancreatitis to 
pancreatic cancer. 
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2.0 GENETICS OF PANCREATIC CANCER 
Myriad of genetic pathways have been shown to be involved in causation of PC that could be involved in 
cell growth regulation or cell proliferation. In a landmark study by Jones et.al. (Jones S et al. 2008) where 
all the exons from tumor DNA of 20661 protein coding genes were sequenced from 24 advanced 
pancreatic adenocarcinoma patients, multiple genetic pathways including 9 DNA repair genes were found 
to be mutated more than once with TP53, ERCC4 and ERCC6 being most frequent genes carrying 
deleterious mutations in about 83% of the cases thus giving rise to the question that are critical DNA 
repair gene mutation vital to the PC pathogenesis process? Given the role of the DNA repair system as the 
guardian of the genome, it is expected that the various DNA repair mechanisms would act to repair the 
damaged DNA and thus prevent the increased cell turnover by preventing them from acquiring a mutator 
phenotype. However if there are defects in the DNA repair mechanism, they will allow the accumulation 
of damaged DNA and thus facilitate the transition from an inflammatory to a metastatic process by 
improper regulation of signal transduction, embryonic signaling and related pathways. 
Thus multiple DNA repair based studies of PC has been undertaken in the past to study the 
functional effects of genetic variations or to look at how genetic variations in various DNA repair genes 
might interact with environmental factors to influence PC risk or how they might affect overall survival or 
overall outcome in PC cases.  
2.1 REVIEW OF DNA REPAIR STUDIES IN PANCREATIC CANCER 
A pubmed search of the keywords “DNA repair” and “pancreatic cancer” in the last 10 years (2003-2012) 
yielded 213 articles of which 19 studies have been genetic epidemiology based looking at role of DNA 
repair genes in PC either as genetic variations that interact with dietary intake factors to modulate risk of 
PC or if SNPs were associated with increased risk of PC, overall survival or simply as a potential marker 
of tumor response to therapeutic measures. SNP based studies have also looked at potential interaction 
with environmental risk factors like smoking and diabetes or simply interactions among SNPs or genes. 
Studies looking at multiple SNPs in high LD in a particular gene have also looked at haplotypes as 
potential indicator of overall survival or simply as risk factor for PC.  
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All the four traditional DNA repair pathways (base excision repair, nucleotide excision repair, 
mismatch repair and double strand break repair) have been studied in pancreatic cancer via genetic 
association studies. In probably the largest of such studies till date by McWilliams et al. (McWilliams RR 
et al. 2009), 236 tag SNPs among all NER genes were investigated in 1143 PC cases and 1097 healthy 
controls and MMS19L was the gene that appeared to be significant in both the corrected and uncorrected 
analysis. However this study had some major limitations in that there was a genotyping failure in 5% of 
the samples that could significantly affect the power and results of this study. Further there was no 
correction for multiple testing which could typically overestimate the significance of the SNPs tested for. 
In the same year, another large case control study from Li et al. (Li D et al. 2009) at the M.D. Anderson 
Cancer Center investigated 9 previous clinically investigated SNPs of the genes hOGG1, LIG3, LIG4, 
POLB, ATM, RAD54L and RECQL on risk of PC and reported that the LIG3 p.G39A and ATM p.D1853N 
SNP homozygote variant had significant interaction with diabetes on risk of PC. Although this was the 
first well designed study to show the possible involvement of genes involved in repair of DNA strand 
breaks or cellular response to DNA damage in risk of PC, it had low frequency of homozygous mutants 
and interaction of genotype with other risk factors thus leaving the requirement of a larger population 
based study to validate these findings. Further the authors pointed out that some observations could be 
false discovery associated with multiple testing issues plus the limited number of genes and SNPs studied 
restricts the usefulness of their findings. Besides, lack of studies exploring the functional significance of 
these SNPs also limits the significance of these findings.  
Moreover, shortcomings such as those reported by Li et al. including heterogeneity of patient 
group which can result in different penetration of a variant as per ethnic differences can also result in 
over-estimation or under-estimation of the true effect of a variant such as the fact that this was the first 
study that showed that BER variants had an effect on PC outcome. Thus the relatively low frequency of 
PC and heterogeneous nature of the studies also limits the potential usage of the association study 
findings as screening tools or as determiners of therapeutic outcome. 
Although these studies have advanced the knowledge of the involvement of DNA repair 
pathways in PC, the rapid progress of PC to metastasis from initial Pan-IN lesions coupled with the fact 
that genetic association does not imply causation, has resulted in no significant therapeutic or preventive 
measures based on the genetic profile of the DNA repair genes in an individual. 
Furthermore pancreatic cancer in general is a complex disease with multiple potential pathways 
being disrupted and multiple genetic variants could be simultaneously acting to give rise to genomic 
instability that is characteristic of cancers. This is a critical factor not addressed by the previous genetic 
association studies which has attempted to implicate single variants in the causation of the disease.  
Besides, the extremely poor prognosis of PC where the 6 month survival rate is less than 5% as reported 
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by literature limits the recruitment of large patient population groups from multiple centers to address the 
issues of small sample size, lack of replication set, heterogeneity of patients and potential for false 
positive comparisons due to multiple comparisons.    
In order to fulfill the deficiency left by genetic association studies, functional studies that rely on 
cell culture and animal models and other in vitro techniques to explain how disruption of a normal 
physiologic process is involved in disease causation have been undertaken and several of these have been 
landmark papers in their contribution to the understanding of role of DNA repair genes in PC. 
In one of the very first of these studies by Crnogorac-Jarcevic (Crnogorac-Jurcevic et al. 2002) 
comparing pure neoplastic and normal duct cells of the pancreas using cDNA microarray, the base 
excision repair gene XRCC1 was found to be significantly downregulated in PC tissues as compared to 
normal tissues. Further they detected reduced immunoreactivity in 75% of cancer cells for XRCC1 as 
compared to a strong nuclear and cytoplasmic immunoreactivity of non-neoplastic pancreatic epithelial 
cells. The findings of this study were supported from another study by Mathews et. al. in 2011 (Mathews 
LA et al. 2011) who sought to investigate the gene expression profile of highly invasive PC cells using an 
in-vitro assay and found that invasive PC cells have significantly elevated levels of DNA repair genes and 
they hypothesized that it was perhaps due to greater accumulation of genomic changes in the highly 
invasive cells. However traditional cDNA microarray studies suffer from several limitations including 
low density compared to oligonucleotide arrays, presence of repetitive and common sequences from gene 
families that would be present in all cDNA from a particular family of genes thus giving rise to potential 
for cross hybridizations and false signals. Thus these findings need to be followed up by further 
expression studies in PC cell lines to add to their validity. 
Genomic instability has always been found to be reported as the root cause of cancers and thus 
studies addressing repair potential of cancerous cell line for specific genomic defects have always gained 
attention. In one of the very first of the studies by Maple et. al. (Maple JT et al. 2005) assessing 35 long 
term survivors of PC ruled out defective MMR as being common in PC and as potential survival benefiter 
of those with sporadic cancer. However majority of patients in this subset of long-term survivors had 
small tumors, negative surgical margins, and adjuvant chemoradiation all of which could be potential 
confounding factors limiting the findings of this study. Further Nyaga et. al. (Nyagi SG et al. 2008) 
analyzing the effectiveness of a PC cell line to repair 8-hydroxyguanine relative to a non-malignant cell 
line reported that there was significant down regulation of the BER pathway gene hOGG1 protein and 
mRNA level compared to the control leading to accumulation of 8-hydroxyguanine thus overwhelming 
the DNA repair genes leading to increased probability of deleterious mutations accumulating and hence 
risk of PC. Indeed one of the most vital BER genes, XRCC1, has repeatedly been detected as a predictor 
of survival in PC patients either those treated by platinum and fluoropyrimidine or as overall determiner 
8
of survival in those with resectable pancreatic adenocarcinoma albeit with conflicting findings. Akita et. 
al. in 2009 (Akita H et al. 2009) attempting to identify relationship between protein expressions and 
clinical outcomes in PC patients who underwent surgery, including response to gemcitabine at the time of 
disease recurrence reported that patients with high ERCC1 had a trend of better overall survival and in 
combination with RRM1 had better overall and disease free survival but in a recent study Maithel et. al. 
(Maithel SK et al. 2011) from their immunohistochemistry results of 95 patients who underwent 
pancreaticoduodenectomy reported that high ERCC1 was associated with both reduced recurrence free 
survival and overall survival after resection. Unless there are more studies addressing the role of ERCC1 
in survival of PC patients, these conflicting results limit their utility. Thus contradictory results along with 
the fact that functional studies in vitro cannot exactly replicate the events occurring in vivo limit the 
findings of functional studies as a potential for better diagnosis or treatment options for PC 
Despite significant contribution to understanding the role of DNA repair defects in PC, single 
variant association studies have suffered from their problems including lack of replication, multiple 
testing and insignificant information regarding effects of single variants on PC causation that were tested 
using genetic association study and limited contribution of functional studies to pancreatic cancer 
treatment. With a hope to fulfill the deficiencies left by single variant association and functional studies, 
genome wide association studies that focus on genotyping multiple tag SNPs all throught the genome 
came to the fore. 
2.2 GENOME WIDE ASSOCIATION STUDIES AND PANCREATIC CANCER 
With the advent of advanced genotyping technology, genome-wide association studies that attempt to find 
multiple tag SNPs and possible suspect genes have become very popular for studying the genetic factors 
for complex diseases and multiple PC GWAS studies have been done since the inception of this 
technology. 
The first PC GWAS study reported in 2009 by Amundadottir et. al. (Amundadottir et. al. 2009) in 
a Caucasian population found an increased susceptibility between a SNP in the intronic region of ABO 
blood group gene and PC risk suggesting that people with blood group O may have a lower risk of 
pancreatic cancer than those with groups A or B. However this finding has not been replicated in any 
other GWAS study despite being previously associated in other non-genome wide association studies. 
Indeed a key feature of all the genome wide association studies in PC is the lack of replication of the 
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findings across the studies or the lack of common genes across the studies suggesting that either ethnicity 
is a major factor determining PC risk or that PC is a highly complex disease with multiple genes and the 
risk posed by each gene for the disease depends on the population being studied. Further relatively limited 
knowledge regarding the role of highly significant SNPs in the non-coding regions of the genome limits 
the significance of the findings in terms of having a clinical relevance. Recent failure of replication 
studies of a Chinese and a Japanese GWAS in a European population such as those by reported by Campa 
et. al. (Campa  et. al. 2009) indicates that fairly common variants despite high levels of significance might 
have arisen just by chance in GWAS studies as well as there is sufficient heterogeneity between 
population studied for any common gene to possess risk across any population. Further the findings of 
variants in non-coding region with odds ratios ranging from 1 to 2 makes it fairly difficult to identify how 
significant the role is of that particular SNP or gene in the disease pathogenesis or what is its exact role.  
Finally one of the key issues which genome wide association studies that attempt to find common variants 
involved with the disease fails to address is that of missing heritability. The common variants are not able 
to account for all the genotypic heritable traits that combine with the environmental effects to give rise to 
a particular phenotype. Thus despite multiple genes being found to be associated with PC pathogenesis in 
the last couple of years via genome wide significant studies, the findings have not been of sufficient 
clinical relevance and next generation sequencing studies and more specifically exome sequencing studies 
that can identify rare deleterious non-synonymous variants have currently emerged as one of the 
predominant modes of studying cancer genomics. 
2.3 NEXT GENERATION SEQUENCING STUDIES 
The advances in next generation sequencing have helped to make it possible to replace laborious 
techniques such as positional cloning to identify genetic changes in both rare and common diseases. With 
the significantly large amount of data generated by next generation sequencing coupled with the 
computational burden of analyzing it, whole exome sequencing has taken precedence over whole genome 
sequencing to identify pathogenic genetic factors for various diseases. The whole exome platform consists 
of all the exons of a genome that are transcribed into mature mRNA. A major reason to focus on the 
exome as compared to the whole genome other than the cost efficiency is the fact that even though the 
exome constitutes only 1% of the genome, it consists of about 85% of the mutations that affect disease 
traits. (Bamshad MJ et al. 2011) Following is the standard workflow often adopted in exome sequencing 
studies: 
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Figure 2.1: General Work flow of exome sequencing studies from isolation of DNA till identification of 
potential disease causing mutations. The workflow has three components: a) Sample Preparation and 
Sequencing, b) Primary Data Processing, c) Secondary Data Processing.  
Figure directly adapted from Chee- Seng Ku et al. 2012 
Although exome sequencing has been significantly successful in identifying genetic variations 
that might disrupt normal physiological process and hence be involved in disease causation especially rare 
Mendelian diseases or diseases within a family, the concept of being able to capture the coding regions of 
the genome have also spawned cancer genome based studies to identify the mutation profile of cancer 
patients. Following the increased efficiency and resolution of next generation sequencing that facilitates 
detection of genetic and genomic alterations such as mutations, insertions, deletions, as well chromosomal 
rearrangements and copy number variations, comprehensive analysis of cancer genome through these 
studies have significantly increased our understanding of the challenges in cancer biology, diagnosis and 
therapy. 
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2.3.1 EXOME SEQUENCING 
Exome sequencing is the process of targeted resequencing of the protein coding regions of the human 
genome to identify disease causing mutations. Sample is prepared by using exome capturing arrays or 
libraries which help in isolating and enriching the DNA template to be analyzed. Following sequencing, 
quality estimation allows the evaluation of each analyzed base and the reads generated are mapped onto 
the reference genome. In order to gain first insights into library preparation and sequencing efficiency, 
filtering steps are required to determine the percentage of sequence reads which do not originate from 
protein coding regions or could not be aligned at all. Subsequently, variant detection algorithms obtain a 
set of genome positions where the analyzed sample differs significantly from the reference. Since these 
call sets contain numerous non-biologically based variations, further filtering steps are applied to increase 
the number of true biological variants. Exome sequencing contains the following major steps in its 
workflow: 
2.3.1.1 Base/color calling quality assignment-In order to determine the accuracy of the base called, 
a certain quality score is assigned known as phred scale quality values for each base or color call. Initially 
introduced by the base-calling program Phred, it links error probabilities logarithmically to a base or color 
call. It is defined as: 
qphred = −10 · log10 (p) 
where p is the estimated error probability for that call.  
2.3.1.2 Alignment- Alignment can be described as the process of determining the most likely source 
within the genome sequence for the observed DNA sequence read, given the knowledge of which species 
the sequence came from.  
Traditional alignment algorithms such as BLAST or BLAT do not scale well with NGS reads in 
terms of processing time, mapping accuracy and memory use. Thus new alignments for aligning short 
reads to the reference genome have been developed specifically for this purpose.  
These programs generally use a strategy where heuristic techniques first identify a small subset of 
reference genome where the read is most likely to align and then a slower and more accurate algorithm is 
used to determine exact position of sequence read.  
Short read aligners is divided in Burrows-Wheeler transform (BWT, (Burrows and Wheeler 
1994) and hash table based algorithms. Hash table aligners index the read sequences and search through 
the reference genome or vice-versa. Read indexing algorithm do not need much memory but may be 
12
inefficient for aligning small amount of reads while reference indexing methods need large memory 
capacities. BWT based aligners use a reversible compression algorithm to build a reference index suffix 
tree and then search within this suffix tree for possible alignments. The BWT index needs only a fraction 
for the whole genome sequence alignment as compared to hash table based methods. 
In order to handle lack of accuracy in alignments, Li et. al.(Li et. al. 2008) introduced the 
mapping quality concept which is the measure of confidence that a read actually originated from the 
position it was aligned to by the mapping program. They consider a read alignment as an estimate of the 
true alignment and calculate the mapping quality Qs  by phred scaling the alignment’s error probability P: 
Qs= -10*log10 (P{read is wrongly mapped}) 
Consequently the mapping quality is set to zero for reads that map equally well to multiple 
positions in the genome. It is common practice to apply mapping qualities to 255 to indicate that mapping 
quality is not available. As paired end reads combine information of both DNA fragment sides, their 
mapping quality QP is calculated as QP =Qs1 + Qs2 . This applies only when both alignments are consistent 
that is the insert size and alignment directions are both correct. If the alignments do not add up, then both 
reads will be treated as SE regarding their mapping quality score calculations.  
2.3.1.3 Variant detection- The main role of exome sequencing is to detect variants from the reference 
genome to determine genes associated with diseases. SNPs are determined by the comparison of an 
assembled consensus sequence which represents the most likely genotype based on the analyzed sequence 
reads with its reference genome. Simple variant detection approaches apply fixed filters based on 
percentage of reads containing the same non-reference base call while more advanced methods use a 
Bayesian approach in combination with prior genotype probabilities to infer the genotype and detect 
variants. Most of these methods differ in their estimated prior genotype probabilities and thus different 
quality indices such as base and mapping quality as poor data quality affects SNP calling accuracy.  Phred 
scale quality scores for variant quality estimation determine the probability that a genotype call is wrong.  
2.3.1.4 File Formats- Several file formats have been established for handling data in exome sequencing. 
Following are the most commonly encountered ones: 
2.3.1.4.1 FASTQ Format- The FASTQ format is a text based file format for storing sequence read 
data and associate per base quality read score. It stores sequences and Phred qualities in a single file. It is 
concise and compact. It is closely related to the FASTA sequence file format and thus lacks an explicit 
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definition leading to introduction of several incompatible variants. A FASTQ file normally uses four lines 
per sequence. Following is its description:  
Line 1 begins with a '@' character and is followed by a sequence identifier and an optional description 
(like a FASTA title line). 
Line 2 is the raw sequence letters. 
Line 3 begins with a '+' character and is optionally followed by the same sequence identifier (and any 
description) again. 
Line 4 encodes the quality values for the sequence in Line 2 using ASCII codes, and must contain the 
same number of symbols as letters in the sequence. 
A FASTQ file containing a single sequence might look like this: 
@EAS100R:136:FC706VJ:2:2104:15343:197393 1:Y:18:ATCAG 
GATTTGGGGTTCAAAGCAGTATCGATCAAATAGTAAATCCATTTGTTCAACTCACAGTTT 
+ 
!*((((***+))%%%++)(%%%%).1***-+*))**55CCF>>>>>>CCCCCCC65 
2.3.1.4.2 SAM and BAM Format- The SAM format was designed to store nucleotides in a generic 
way. It consists of one header section and one alignment section. The lines in the header section start with 
character ‘@’, and lines in the alignment section do not. All lines are TAB delimited and each alignment 
has 11 mandatory fields and a variable number of optional fields. The mandatory fields are shown in the 
figure below. 
Figure 2.2: A SAM format file mandatory fields. 
Figure directly adopted from Li et. al. 2009 
14
They must be present but their value can be a ‘*’or a zero (depending on the field) if the 
corresponding information is unavailable. The optional fields are presented as key-value pairs in the 
format of TAG: TYPE: VALUE. They store extra information from the platform or aligner. For example, 
the 
‘RG’ tag keeps the ‘read group’ information for each read. In combination with the ‘@RG’ 
header lines, this tag allows each read to be labeled with metadata about its origin, sequencing center and 
library. The SAM format specification gives a detailed description of each field and the predefined TAGs. 
The standard CIGAR description of pair wise alignment defines three operations: ‘M’ for 
match/mismatch, ‘I’ for insertion compared with the reference and ‘D’ for deletion. The extended CIGAR 
proposed in SAM added four more operations: ‘N’ for skipped bases on the reference, ‘S’ for soft 
clipping, ‘H’ for hard clipping and ‘P’ for padding. These support splicing, clipping, multi-part and 
padded alignments.  
Further additional optional fields also allow for the documentation of less important or program 
specific data. Color space read information is also described in the optional fields  
To improve the performance, a companion format Binary Alignment/Map (BAM) was designed, 
which is the binary representation of SAM and keeps exactly the same information as SAM. BAM is 
compressed by the BGZF library, a generic library that was developed to achieve fast random access in a 
zlib-compatible compressed file. Majority of the space in the BAM file is used to store the base qualities. 
2.3.1.4.3 Variant Call Format (VCF)- The variant call format (VCF) is a generic format for storing 
DNA polymorphism data such as SNPs, insertions, deletions and structural variants, together with rich 
annotations. VCF is usually stored in a compressed manner and can be indexed for fast data retrieval of 
variants from a range of positions on the reference genome. The format was developed for the 1000 
Genomes Project.   
A VCF file is divided into a header and a body section where each header line is identified by a 
leading ‘#’. The header stores mandatory information about the file format version and body content. 
Optional header lines contain meta-data about annotations in the VCF body section. The most common 
annotations include genotype likelihoods, dbSNP membership, ancestral allele, read depth and mapping 
quality.  
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Figure 2.3: A VCF file format with its header.  
Figure directly adapted from Danecek et. al. 2011 
2.3.2 EXOME SEQUENCING AND PANCREATIC CANCER 
In order to overcome the loopholes left by association and functional in vitro studies, next generation or 
massively parallel sequencing studies have developed that are assisted by the completion of the human 
genome project.  
The advantage of massively parallel sequencing (MPS) technology is that they have transformed 
approaches to data generation enabling the sequencing of an entire human genome region of interest 
within a very short period of time of less than 2 weeks. These studies have facilitated the comparison of 
cancers of matched tumor and normal genomes that has significantly increased our understanding of 
cancer genome biology. They work by shearing the normal DNA into small fragments which are then 
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amplified and sequenced and mapped back to the reference genome following which sophisticated 
computational and statistical tools are used to make variant calls.  
One of the applications of MPS is exome sequencing that captures the coding regions of the 
genome using whole genome MPS libraries that effects the nucleic acid hybridization between the 
genome or genomes of interest and the exome capture probes. Although this approach captures only about 
1.8% of the genome, it serves as an outstanding first pass for detecting genes or variations of interest as 
compared to whole genome approach that generates data with excessively large computational burden of 
analysis or genome wide associations studies which detects variants with moderate odds ratios in 
potentially non-coding regions of the genome which are hard to interpret.   
Genetic studies of PC taking advantage of this latest advent in sequencing technology have taken 
place in the last few years. In one of the very first of these studies by Jones et. al. (Jones S et al. 2008), 
twenty four advanced pancreatic adenocarcinoma had their exonic regions sequenced and among all the 
core signaling pathways found to be altered, DNA damage control was among the most common ones 
with 9 genes found to be altered and 83% of the tumors had at least one of the 9 genes altered. Further 
Wang et. al. (Wang L et al. 2012) investigating 15 pancreatic ductal adenocarcinomas and matched 
control for genomic changes using exome sequencing which were validated by RNA sequencing found 
that the most frequently mutated genes were the cell cycle gene CDKN2A along with DNA repair genes 
TP53 and SMAD4. With sporadic pancreatic cancers being well known for increased rates of 
microsatellite instability and in keeping with this notion, the DNA mismatch repair gene MLH1 was to 
found have an increased mutation rate in the cell lines with high variations in general and the MLH1 
expression level correlated with the mutation rates. In another study by Roberts et. al. (Roberts NJ et al. 
2012) that utilized exome sequencing for investigating the genetic basis of familial PC (FPC) which is 
still yet unknown showed that potentially deleterious non-sense mutations of the ATM gene were 
segregating with pancreatic cancer disease status in two families who met the clinical criteria for FPC.  
Thus next generation sequencing when applied with appropriate caution has the potentiality of 
identifying disease causing mutations as opposed to associated mutations from previous association 
studies and holds the potentiality of spurring on further functional studies to identify how disruptions in 
these genes are related to the PC pathogenesis. 
2.3.3 THE 1000 GENOMES PROJECT: A CATALOGUE OF HUMAN GENETIC 
VARIATION 
The International HapMap project completed in 2003 aimed to determine the common pattern of DNA 
sequence variation in human genome by characterizing sequence variants and their frequencies spawned 
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studies focusing on genome-wide search for common variants for disease risk. These studies better known 
as genome-wide association studies were carried out on multiple different diseases and with sufficient 
statistical rigor led to identification of variants that were highly significant in disease causation. However 
a major drawback of these studies were that although they helped identify hitherto unknown genes for 
common diseases, highly significant variants in non-coding regions of the genome proved difficult to 
interpret and only explained a fraction of the heritability of a disease. Especially faced with difficulty of 
interpreting the role of highly significant variants in the non-coding regions of the genome, in 2009 the 
first human whole exome sequencing study was reported (Ng SB et al. 2009) that was carried out on 8 
HapMap individuals and 4 unrelated individuals of a rare dominantly inherited disorder known as 
Freeman-Sheldon syndrome. This study showed that candidate genes for monogenic disorders could be 
identified by exome sequencing of a small number of unrelated, affected individuals and further this 
strategy could be extended to diseases with more complex genetics through larger sample sizes and 
appropriate weighting of nonsynonymous variants by predicted functional impact.  
Thus exome sequencing with its ability to target all the coding regions of the known genes in the 
human genome spawned the largest study of to identify variants in the human genome’s coding region. 
This project known as the 1000 genomes project aimed to discover genotype and provide accurate 
haplotype information on all types of DNA polymorphisms in multiple different population groups. 
(Genomes Project C et al. 2010)  
Briefly the 1000 genomes project consisted of three sub-projects namely the trio project, followed 
by the low-coverage project and the exon project. The trio project consisted of whole genome shotgun 
sequencing at high coverage (average 42x) of two families of the hapmap population groups YRI and 
CEU. The low coverage project (2-6x) was performed in 179 individuals from the YRI, CEU, CHB and 
JPT Hapmap population groups. The final and exon project targeted 8140 exons from 906 randomly 
selected genes followed by sequencing them at high coverage of greater than 50X on average in 697 
individuals from 7 populations groups of Africa, Europe and East Asia.  
A total of approximately 15 million SNPs, 1 million short insertions and deletions and 20000 
structural variants were discovered with union across of the projects. Of these variations, approximately 
55% of the SNPs and 57% of the insertion/deletions were novel having not been found in the dbSNP 
previously. With respect to the number of variants found to cause synonymous or non-synonymous amino 
acid changes, it was found that an individual differs from the reference human genome at 10000-11000 
non-synonymous sites in addition to 10000-12000 synonymous sites. However the number were much 
lower for insertion deletions with an average of 190-210 in-frame indels and 220-250 deletions that shift 
the reading frame per individual.   
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With such a huge repertoire of human genetic variation data, the 1000 genomes project 
potentially serves as an efficient filtering tool for removing potentially non-deleterious mutations 
generated by exome sequencing data as well as identify rare variants that could be potentially risk variants 
for disease causation.  
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3.0 SHORTLIST OF GENES SELECTED FOR STUDY 
With the focus solely being on the DNA repair genes, 156 DNA repair genes as curated by the UPMC 
dnapitt crew (https://dnapittcrew.upmc.com/db/orthologs.php) was included for analysis. Following is a 
list of the genes with the respective pathways they are involved in: 
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Table 3.1 DNA repair pathways along with genes for each pathway included for study 
DNA REPAIR PATHWAY GENES INVOLVED 
BER APEX1, APEX2, LIG3, MBD4, MPG, MUTYH, 
NEIL1, NEIL2, NEIL3, NTHL1, OGG1, PARG, 
     CHROMATIN STRUCTURE CHAF1A, H2AFX 
CONSERVED DDR CHEK1, CHEK2, HUS1, RAD1, RAD17, RAD9A, 
RRM1, RRM2B, TP53, ATR, ATRIP 
DIRECT REVERSAL OF DAMAGE ALKBH3, ALKBH2, MGMT 
DNA POL MAD2L2, PCNA, POLA, POLB, POLD1, POLE, 
POLG, POLH, POLI, POLK, POLL, POLM, 
                    EDITING & PERFORMING 
ENDONUCLEASE 
EXO1, FEN1, ENDOV, SPO11, TREX1, TREX2 
FANCONI ANEMIA FANCA, FANCE, FANCB, FANCC, FANCD2, 
FANCF, FANCG, FANCI, FANCL, FANCM 
GENES DEFECTIVE IN DISEASE ATM, BLM, RECQL4, WRN 
HOMOLOGOUS RECOMBINATION BRCA1, BRCA2, DMC1, EME1, GEN1, 
MRE11A, MUS81, NBN, RAD21, RAD50, 
    MMR MLH1, MLH3, MSH2, MSH3, MSH4, MSH5, 
MSH6, PMS1, PMS2 
MODULATION OF NUCLEOTIDE 
POOL 
DUT, NUDT1, RRM2B 
NER RELATED ERCC8, DDB1, DDB2, ERCC6, MMS19, TFF2, 
XAB2 
NHEJ DCLRE1C, PRKDC, SIRT1, XRCC4, XRCC5, 
XRCC6, LIG4 
NER CCNH, CDK7, CETN2, ERCC1, ERCC2, ERCC3, 
ERCC4, ERCC5, FBXL2, GTF2H1, GTF2H2, 
    OTHER SUSPECTED GENE APTX, DCLRE1A, DCLRE1B, RAD52B/RDM1, 
RECQL, RECQL5, RPA4 
RAD6 PATHWAY RAD18, UBE2A, UBE2B, UBE2N, UBE2V2 
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4.0 HYPOTHESIS 
Based on the previous findings of the confirmed role of DNA repair genes in PC and the success to 
exome sequencing till date to develop further insights into PC pathogenesis, this technology was utilized 
to test the following hypothesis:      
1. Individuals with both germline mutations and inflammatory conditions (CP) with PC have a higher
genetic risk of PC as compared to long term CP individuals who have not progressed on to PC. 
2. The pancreas primarily utilizes a subset of DNA repair mechanisms and defects in these mechanisms
give the chronic pancreatitis individuals an increased risk of PC as compared to the general population. 
3. Rare variants that result in amino acid changes in the DNA repair genes are present in significantly
greater number in CP+PC individuals as compared to the CP-PC individuals and thus contribute to greater 
PC risk.. 
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5.0 PREMISE 
PC is a result of prior present inherited and acquired germline mutations and modifications. Increased risk 
occurs with inherited heterozygous mutations with a greaterprobability for a loss of the the second allele 
when duct cells are continuously exposed to reactive oxygen species and other toxic inflammatory factors 
that can cause DNA damage. An increased injury and cell turnover in an oxidative environment favors 
accumulation of mutations that might give a selective growth advantage to apparently normal cells which 
go on to develop malignant tumors via uncontrolled proliferation. The table in appendix A shows the 
inherited germline mutations that have been detected in the genetic studies of inherited PC. (Solomon S 
et. al. 2012) 
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6.0 MATERIAL & METHODS 
 6.1 SELECTION OF STUDY SUBJECTS 
A total of 16 patients who had chronic pancreatitis before pancreatic cancer and 11 individuals who had 
long standing chronic pancreatitis were selected for the study. These individuals were either part of the 
North American Pancreatitis Study 2 (NAPS2) or the Hereditary Pancreatitis study (HP) or the Pancreatic 
Adenocarcinoma Gene-Environment Risk (PAGER) study. 
Follow-up had been completed on the subset enrolled at Pittsburgh and patients with CP who 
developed pancreatic cancer had been identified. PAGER represents a cohort of patients with pancreatic 
cancer that were ascertained using the same instruments as NAPS2 and HP 
The primary criteria for selection is prospectively ascertained patients in the NAPS2, HP and 
PAGER studies with documented chronic pancreatitis for more than 3 years prior to the diagnosis of 
pancreatic cancer. 
6.2 RATIONALE OF STUDY DESIGN 
Next generation sequencing has made it possible to identify genetic differences among two different 
groups of study subjects by scanning the specific regions of the genome leading to identification of 
possible changes in protein sequence or other changes in regulatory mechanisms that might be involved in 
disease causation. Specifically massively parallel sequencing technologies that produce raw data with 
high quality scores and relatively high read depth can accurately identify subtle variations between two 
different groups of individuals without having to study very large population groups.  
One of the most commonly applied massively parallel sequencing technologies is whole exome 
sequencing that involves sequencing of the coding regions (CDS) and untranscribed regions (UTR) of all 
the known genes in the genome. Highly malignant diseases like various forms of cancer have been 
studied using this technology and have led to identification of disease causing variants that are likely to be 
effective therapeutic targets for the future. 
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This technology has been applied here to identify variants in the coding regions of the genomic 
DNA of the DNA repair genes from 16 pancreatic cancer individuals who progressed on to PC from CP. 
The rationale for focusing on genomic DNA is the target to identify variants that give high risk of PC to 
CP individuals as compared to the general population. Despite the human genome consisting of more than 
20000 genes, the logic behind solely focusing on the DNA repair genes is that cancer is a disease that is 
characterized by genomic instability and it is the role of the DNA repair system to maintain the stability 
of genome by removing erroneous genetic changes. Thus if there are germline mutations in the DNA 
repair genes such that their normal function is disrupted leading to non-correction of mutations that arise 
as a result of DNA damage after severe inflammation during chronic inflammatory diseases that exposes 
the tissues of the organ to cytotoxic agents such as proinflammatory cytokines and reactive oxygen 
species, then the possibility of those damages remaining unrepaired increase and this increases the 
instability of the genome which can undergo further spontaneous mutations that is characteristic of cancer 
genomes. Their presence would lead to activation of cellular protective mechanisms, such as cell death 
and increased proliferation aiming at organ regeneration. Increased cell turnover in an environment rich in 
oxidative species favors accumulation of DNA damage thus increasing chances of positive selection for 
mutations that confer growth advantage and hence increases the risk of cancer. Further only variant 
positions that were heterozygous were included in the analysis. A reason for doing that is genomic DNA 
was chosen for sequencing and if homozygous mutations generated by sequencing of genomic DNA were 
chosen for further analysis and if they happen to be in coding regions that affects the protein function, 
then that affect would be seen in all the cells of the individual and that particular individual could develop 
multiple different cancers or other genetic diseases characterized by loss of function of DNA repair genes. 
Due to the fact that the cancer individuals only developed PC and no other form of cancer, heterozygous 
germline variants would be expected to give the risk with the rationale that loss of the second allele 
during the inflammatory to cancer transition with the increased cell turnover in an environment rich in 
oxidative species would facilitate crossing of the threshold of risk needed for a CP individual to progress 
to PC.  
A major outcome of exome sequencing studies is the identification of thousands of variants most 
of which are non-deleterious mutations that differ from the reference genome mainly because of natural 
variations and are not likely to be disruptive to normal functioning of the gene and thus unlikely to be 
pathogenic. Hence a filter is necessary that will help remove these non-pathogenic mutations and limit the 
analysis to variants that could be potentially pathogenic. The 1000 genomes project is a collaborative 
project aims that aims to characterize the human genome sequence for investigating relationships between 
genotype and phenotype. It is one of the largest repositories of human genetic variation data and thus 
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serves as a suitable filter to remove variants that are unlikely to be causal by setting different parameters 
such as allele frequency. The 1000 genome project was discussed in detail earlier. 
Although whole exome sequencing data that has been filtered against 1000 genomes is useful to 
significantly narrow down the potentially causal variant list for a disease, there are still likely to be 
variants that are non-pathogenic and would be difficult to differentiate from the actual causal ones. In 
order to further aid in determining variants of higher risk scores, GERP or genomic evolution rate 
profiling scores were used to quantify amino acid variants. GERP is a framework for identifying 
constrained elements based on the assumptions that purifying constraints result in a relative lack of 
substitution events. GERP estimates evolutionary rates for individual alignment columns, and compares 
these inferred rates with a tree describing the neutral substitution rates relating the species under 
consideration. It subsequently identifies candidate constrained elements by annotating those regions that 
exhibit fewer than expected substitutions. Each of these elements is scored according to the magnitude of 
the substitution deficit, measured as “rejected substitutions” (RS). GERP scores can range from a 
minimum negative value of -6.18 to +12.36 with values above 2 believed to be enriched for truly 
constrained sites. (Cooper GM et. al. 2005)     
6.3 EXPERIMENT SET UP TO TEST HYPOTHESIS 
Hypothesis 1:  Individuals with CP who have progressed on to PC have a greater load of rare and novel 
variants in their DNA repair system as compared to long standing CP patients. 
In order to test the above hypothesis, the rare and novel variant count in the genes of interest was 
determined for all the individuals in the study and then Mann-Whitney U test with a standard type one 
error rate of 0.05 was used to check whether CP+PC individuals carried a greater load of rare genetic 
variants in the 159 genes of interest as compared to the CP-PC individuals.   
Hypothesis 2: The pancreas primarily utilizes a subset of DNA repair mechanisms and defects in these 
mechanisms give the chronic pancreatitis individuals an increased risk of PC as compared to the general 
population. 
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In order to test the above hypothesis, the rare and novel variant count for each pathway as defined 
previously was determined for all the individuals in the study and Mann- Whitney U test was used to 
check which pathways had a greater load of rare variants in CP+PC individuals as compared to CP-PC 
individuals. 
Hypothesis 3: Rare variants that result in amino acid changes in the DNA repair genes are at highly 
conserved positions and thus contribute to PC risk as compared to non-cancerous individuals 
In order to test the above hypothesis, rare variants that result in amino acid changes were annotated using 
GERP scores and the Mann-Whitney U test was used to test the hypothesis that CP+PC individuals had a 
greater mean number of variants causing amino acid changes in the 159 genes of interest as compared to 
the CP-PC individuals. 
As per the GERP score guidelines, only RS score threshold of above 2 was considered as providing 
evidence for a highly sensitive site.  
6.4 ANNOTATION OF VCF FILE 
The VCF file for each variant was annotated using the tool ANNOVAR. (Wang K et. al. 2010) Briefly the 
annotation files that ANNOVAR utilizes for annotating a set of variants was downloaded from the web 
using ANNOVAR generated shell scripts and then each VCF file was annotated against the 1000 
genomes data to determine variant 1000G minor allele frequency of variants present in 1000G and to 
identify variants that were novel. The two files generated one with variants novel to 1000 genomes and 
the other with variants present in 1000 genomes were then again annotated using ANNOVAR to 
determine the gene, transcript, amino acid change and region of gene where variant is located for each of 
the heterozygous variant. Each ANNOVAR input file generated two output files after filtering against 
1000G and each of these files when annotated using ANNOVAR to identify gene and amino acid changes 
generated two files one with the gene and region where variation is located and the other with the variants 
known to effect the protein sequence. 
The latest version of the ANNOVAR tool that was installed at FRANK core of the Simulation 
and Modelling (SAM) Centre of the University of Pittsburgh was used for annotating the variants via 
UNIX command prompts.  
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The ANNOVAR specified shell script was used to download the database that ANNOVAR uses 
for annotation and then utilize them to annotate the variants. Following are the scripts used and the 
snapshot of the file generated by ANNOVAR. 
In order to download the annotation file that ANNOVAR uses for annotating against the thousand 
genomes project, the following script is used. 
annotate_variation.pl -downdb 1000g2012dec_all humandb -buildver hg19 /home/dwhitcomb/sid10 
In order to download the annotation file that ANNOVAR uses for annotating variants with gene 
and amino acid changes, the following script is used. 
annotate_variation.pl -downdb -buildver hg19 refGene /home/dwhitcomb/sid10 
In order to download the annotation file for determining GERP scores, the following script is 
used. 
annotate_variation.pl -downdb ljb_all -buildver hg19 -webfrom annovar /home/dwhitcomb/sid10 
In order to convert the VCF file to an ANNOVAR input file using a sample file HET_ONLY, 
following script is used. 
convert2annovar.pl –format vcf4 –includeinfo /home/dwhitcomb/sid10/ONLY_HET/HET_ONLY.vcf > 
/home/dwhitcomb/sid10/HET_ONLY.avinput (where HET_ONLY is symbolic of an input VCF file and 
HET_ONLY.avinput is an ANNOVAR input format file generated that is used for further annotation) 
Below are the snapshot of a VCF file and the corresponding ANNOVAR input file. 
Figure 6.1: Snapshot of a VCF file 
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Figure 6.2: Snapshot of a VCF file converted to ANNOVAR format 
In order to annotate an ANNOVAR file against the 1000 genomes data, using a sample file 
HET_ONLY, following script is used: 
cat /home/dwhitcomb/sid10/HET_ONLY.avinput | annotate_variation.pl --filter --dbtype 
1000g2012apr_all --buildver hg19 /home/dwhitcomb/sid10/HET_ONLY.avinput /home/dwhitcomb/sid10 
(generates two files one with variants present in 1000 genomes and their corresponding MAF and the 
other with variants novel to 1000 genomes) 
Below are the snapshots of the files generated where one contains all the variants found in the 
1000 genomes project with their corresponding minor allele frequency and the other contains all the novel 
variants. 
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Figure 6.3: Snapshot of an ANNOVAR file after annotating with thousand genomes minor allele 
frequency displaying variants present in the thousand genomes project 
Figure 6.4: Snapshot of an ANNOVAR file after annotating with thousand genomes minor allele 
frequency displaying variants absent in the thousand genomes project 
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In order to annotate the rare variants with minor allele frequency of less than 0.01 and novel 
variants, the file containing the variants present in the thousand genomes project was edited in excel and 
only those variants that were rare were annotated with gene and amino acid changes. Following is the 
script used: 
cat /home/dwhitcomb/sid10/HET_ONLY.avinput.hg19_ALL.sites.2012_04_dropped 
|annotate_variation.pl --buildver hg19 
/home/dwhitcomb/sid10/HET_ONLY.avinput.hg19_ALL.sites.2012_04_filtered /home/dwhitcomb/sid10 
Following is the snapshots of the files generated by ANNOVAR. 
Figure 6.5: Snapshot of an ANNOVAR file showing genes and region in gene where variants are located. 
31
Figure 6.6: Snapshot of an ANNOVAR file after filtering showing variants that alter the protein sequence 
In order to annotate the amino acid altering variants with GERP scores, the following 
ANNOVAR script was used. 
cat /home/dwhitcomb/sid10/HET_ONLY.avinput | annotate_variation.pl --filter --dbtype ljb_all --
buildver hg19 /home/dwhitcomb/sid10/HET_ONLY.avinput /home/dwhitcomb/sid10 
Following is the snapshot of the file generated by ANNOVAR: 
Figure 6.7: Snapshot of variants that cause an amino acid change with their corresponding GERP score. 
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6.5 STATISTICAL TESTING 
The Mann Whitney U test was used to test the hypothesis that CP+PC individuals have a greater mutation 
load of common, rare, synonymous rare and novel as well protein sequence altering synonymous and 
novel variants as compared to CP-PC individuals. The same test was also used to test the hypothesis that 
specific DNA repair pathways carry a greater load of rare and novel variants in the CP+PC individuals as 
compared to CP-PC individuals. A standard type one error rate of 0.05 was chosen and any p value below 
0.05 was considered as significant. 
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7.0 RESULTS 
7.1 PATIENT CHARACTERISTICS 
A total of 16 CP+PC patients of which 10 were male (Mean age=56, SD=9.1, Range=49-79) and 6 who 
were female (Mean age=55.8, SD=13.36, Range=40-76) were selected for whole exome sequencing. Of 
the 10 male patients, 4 had primary phenotype of CP, with one having a secondary phenotype of 
hereditary pancreatitis and 4 had recurrent acute pancreatitis while the remaining two had a primary 
phenotype of PC. Among the 6 females, two had a primary phenotype of CP while 3 of them had PC as 
the primary phenotype. One of the males with CP also had a secondary phenotype of HP while a second 
male had a secondary phenotype of acute pancreatitis. Two females with primary phenotype of PC also 
had reported family history of PC. 
A major difference between the CP+PC and CP-PC patients is the average age which was greater 
than 50 for the CP+PC patients and less than 30 for the females (p<0.0001) and with this being an 
association study, the significant age difference of the two groups of individuals could be a major 
confounding factor that could distort the association test findings. Thus an age adjustment of the 
association test results was done in all of the later comparisons.   
The details of the patients are listed in the table 7.1 below. 
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Table 7.1 Phenotype and demographic detail of CP+PC patients included in study 
Patient ID Primary phenotype Secondary phenotype Age, Sex, Cancer history 
HP3 45, Female, PC 
HP512 CP HP 76 , Male, PC 
HP637 CP 76, Female, PC 
NAPS232 RAP Male, 66, PC & Parathyroid cancer 
NAPS823 RAP Male, 49, PC & Parathyroid adenoma 
NA20 CP Male, 60, PC 
NA52 RAP Male, 59, PC 
NA63 CP Male, 58, PC 
NA437 CP Male, 79, PC 
NA1066 CP Female, 40, PC 
NA1265 RAP Male, 57, PC 
PA18 PC 64, Female, PC 
PA227 PC AP 69, Male, PC 
PA884 PC Family history of PC 60, Female, PC 
PA1238 PC Family history of PC 50, Female, PC 
PA1306 PC 62, Male, PC 
A total of 11 CP-PC patients of which 7 were male (Mean age=30.4, SD=17.4, Range=12-59) and 
4 of whom were female (Mean age=26, SD=16.5, Range=2-39) were selected for whole exome 
sequencing. Of the 7 male patients, 2 of them had acute pancreatitis as primary phenotype and 5 of them 
had CP. Among the 4 females, two of them had acute pancreatitis while two of them had idiopathic CP. 
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Table 7.2 Phenotype and demographic detail of CP-PC patients included in study 
Patient ID Primary phenotype Secondary phenotype Age, Sex 
HP470 Acute Pancreatitis (AP) 12,M 
HP653 Acute Pancreatitis (AP) 34,F 
HP654 Acute Pancreatitis (AP) 2,F 
HP657 Acute Pancreatitis (AP) Had cholecystectomy at 28yr 39,M 
NA1135 Chronic Pancreatitis 
(CP) (idiopathic) 
gallstones 39,F 
NA1396 Chronic Pancreatitis 
(CP) (alcohol & 
hereditary) 
duct obstruction 59,M 
NA1499 Chronic Pancreatitis 
(CP) (idiopathic) 
duct obstruction 
pancreatic divisum 
15,M 
NA1501 Chronic Pancreatitis 
(CP) (obstructive) 
15,M 
NA324 Chronic Pancreatitis 
(CP) (autoimmune and 
idiopathic) 
32,M 
NA6600 Chronic Pancreatitis 
(CP) (alcoholic) 
41,M 
NA992 Chronic Pancreatitis 
(CP) (idiopathic) 
29,F 
An ANOVA test of the comparison of the mean difference in age of the two groups of patients 
yielded a significant p value of less than 0.0001 which suggests that age could act as a confounder of the 
findings of this association study. However the fact that germline mutations have been investigated which 
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does not change over time eliminates age as a confounding variable. Further the potentiality remains that 
some of these non cancerous patients may go on to develop PC in the future biasing the test towards null 
hypothesis of no significant difference in age and the effects further investigated over here could possibly 
be the same or even larger if the comparison group was confirmed cancer free older participants.  
7.2 EXOME SEQUENCING MAPPING SUMMARY REPORT 
Each PC individual had an average of 48376235 reads (SD=7248196, Range=37167293-62894601) of 
which an average of 84% of reads (SD=0.94, Range=82.81-86.12) mapped uniquely to the reference 
database and an average of 16% of reads (SD=0.94, Range=13.88-17.19) failing to map to the reference 
genome. Table 6.3 below shows that for each CP+PC individual, more than 80% of the reads successfully 
mapped to the reference genome. 
37
Table 7.3 Percentage of mapped and unmapped read for each CP+PC individual 
With regards to distribution of mapped read length, paired end reads that were 75bp long formed 
an average of 98.71% (SD=0.10, Range=98.44-98.78) of the total mapped reads. The table below lists the 
number of mapped 75bp paired end reads and the number of mapped bases covered by it as the 
percentage of total mapped reads. 
Patient 
ID 
Total number of 
reads 
No of mapped reads (% of 
mapped reads) 
No of unmapped reads (% of 
unmapped reads) 
HP3 54008511 44947941 (83.22) 9060570 (16.78) 
HP512 45629884 38513826 (84.4) 7116058 (15.6) 
HP637 42664418 35644087 (83.55) 7020331 (16.45) 
NA20 45937737 39293836 (85.54) 6643901 (14.46) 
NA52 42370995 35088538 (82.81) 7282457 (17.19) 
NA63 50234433 42092016 (83.79) 8142417 (16.21) 
NA232 56855082 47638720 (83.79) 9216362 (16.21) 
NA437 62894601 52546095 (83.55) 10348506 (16.45) 
NA823 45073267 38553787 (85.54) 6519480 (14.46) 
NA1066 53461052 44834817 (83.86) 8626235 (16.14) 
NA1265 52768731 44898646 (85.09) 7870085 (14.91) 
PA18 37167293 31095808 (83.66) 6071485 (16.34) 
PA227 41662025 35045369 (84.12) 6616656 (15.88) 
PA884 57983386 49936887 (86.12) 8046499 (13.88) 
PA1238 43969114 36643806 (83.34) 7325308 (16.66) 
PA1306 41339236 34710146 (83.96) 6629090 (16.04) 
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Table 7.4 Number of 75bp paired end read and percentage of 75bp paired end reads as 
percentage of all mapped reads for each CP+PC individual 
Patient 
ID 
Number of 75bp paired end reads that 
mapped to the reference genome 
Base pairs covered by 75bp paired 
end reads (% of total mapped reads) 
HP3 44387653 3329073975 (99.3) 
HP512 38035542 2852665650 (99.3) 
HP637 35194982 2639623650 (99.3) 
NA20 38809613 2910720975 (99.3) 
NA52 34647990 2598599250 (99.3) 
NA63 41563427 3117257025 (99.3) 
NA232 47039672 3527975400 (99.3) 
NA437 51896161 3892212075 (99.3) 
NA823 38078575 2855893125 (99.3) 
NA1066 44273771 3320532825 (99.3) 
NA1265 44343472 3325760400 (99.3) 
PA18 30702596 2302694700 (99.3) 
PA227 34607919 2595593925 (99.3) 
PA884 49329035 3699677625 (99.3) 
PA1238 36182747 2713706025 (99.3) 
PA1306 34280247 2571018525 (99.3) 
7.3 EXOME SEQUENCING COVERAGE STATISTICS FOR CP+PC INDIVIDUALS 
A major issue in next generation sequencing is whether the data has sufficient coverage in order to make 
variant calls with a high confidence. In the dataset for the 16 CP+PC patients, the average coverage for all 
the cancer patients for all the reads was 34X and for the mapped reads it was 31X suggesting that the 
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overall dataset was of fairly high quality to make variant calls. Following table lists the coverage of all 
reads and mapped reads for the CP+PC individuals. 
Table 7.5: Average coverage of total reads and mapped reads for 16 CP+PC patients 
PATIENT ID COVERAGE OF ALL READS COVERAGE OF MAPPED READS 
HP3 41X 34X 
HP512 35X 29X 
HP637 32X 27X 
NA20 35X 30X 
NA52 32X 27X 
NA63 38X 32X 
NA232 43X 36X 
NA437 48X 40X 
NA823 34X 29X 
NA1066 40X 34X 
NA1265 40X 34X 
PA18 28X 24X 
PA227 32X 27X 
PA884 44X 38X 
PA1238 33X 28X 
PA1306 31X 27X 
7.4 EXOME SEQUENCING VARIANT CALL STATISTICS 
Each of the paired end reads after mapping to the reference genome (NCBI GRCh37/hg19), produced 
homozygous and heterozygous variant calls with the following statistics.  
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Table 7.6 Number of homozygous and heterozygous variant loci for each CP+PC patient 
Patient ID No of homozygous / No of heterozygous variation loci 
HP3 12313/19303 
HP512 10441/18792 
HP637 10419/17930 
NA20 11198/18870 
NA52 10098/17456 
NA63 12253/20255 
NA232 12794/21287 
NA437 13825/23269 
NA823 11429/19304 
NA1066 12595/20920 
NA1265 12661/20849 
PA18 9295/16397 
PA227 9780/16642 
PA884 12285/18886 
PA1238 10332/17557 
PA1306 9819/17042 
7.5 ANNOVAR 1000 GENOMES ANNOTATION RESULTS 
Following annotation of the heterozygous variants using ANNOVAR against the 1000 genomes project 
detected variants, two output files were generated of which one listed the variants present in the genomes 
project with their corresponding 1000 genomes minor allele frequency and one listing the variants novel 
to 1000 genomes. An average of 23852 (SD=1684, Range=21321-27133) heterozygous variants were 
present in each cancer individual of which an average of 20164 (SD=1337, Range=18136-22840) variants 
were present in 1000 genomes. An average of 825 (SD=51, Range=747-924) variants were present in 
1000 genomes at a minor allele frequency of less than 1%.  The following table lists the frequency of the 
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number of variants found in the 1000 genomes, the number of variants that were rare as per the 1000 
genomes minor allele frequency annotations and finally the variants that were novel as per 1000 genomes. 
Table 7.7 Number of rare and novel variants as per thousand genomes annotation for each CP
+PC patient 
Patient 
ID 
Number of 
heterozygous 
variant 
positions 
Number of 
variants 
annotated by 
1000g2012apr 
(as percentage of 
all heterozygous 
variants) 
No of variants 
present in 1000 
genomes that had 
MAF<0.01 (as 
percentage of all 
1000 genomes 
variants) 
Number of variants 
absent in 
1000g2012apr (as 
percentage of all 
heterozygous 
variants) 
HP3 25831 21929 (84.9%) 867 (3.95%) 3630 (14.1%) 
HP512 24065 20404 (84.8%) 850 (4.17%) 3410 (14.1%) 
HP637 23026 19397 (84.2%) 826 (4.26%) 3397 (14.8%) 
NA20 23422 19872 (84.8%) 863 (4.34%) 3336 (14.2%) 
NA63 24969 20709 (82.9%) 879 (4.25%) 3954 (15.8%) 
NA52 22356 19022 (85.1%) 796 (4.19%) 3138 (14.9%) 
NA232 25408 21522 (84.7%) 872 (4.05%) 3601 (14.2%) 
NA437 27133 22840 (84.2%) 924 (4.05%) 3997 (14.7%) 
NA823 24213 20364 (84.1%) 821 (4.03%) 3586 (14.8%) 
NA1066 25450 21343 (83.9%) 854 (4.00%) 3795 (14.9%) 
NA1265 25230 21197 (84%) 790 (3.73%) 3756 (14.9%) 
PA18 21868 18741 (85.7%) 774 (4.13%) 2933 (13.4%) 
PA227 21321 18136 (85.1%) 748 (4.12%) 2983 (14%) 
PA884 22644 19135 (84.5%) 821 (4.29%) 3282 (14.5%) 
PA1238 22646 19084 (84.3%) 773 (4.05%) 3335 (14.7%) 
PA1306 22058 18940 (85.9%) 747 (3.94%) 2939 (13.3%) 
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7.6 ANNOVAR GENE AND AMINO ACID CHANGE ANNOTATION RESULT FOR 
DNA REPAIR GENES IN CP+PC INDIVIDUALS 
Following the gene and amino acid annotation of the variants that were rare and absent as per reported 
1000 genomes, minor allele frequency, only variants corresponding to the variants in the 159 genes of 
interest were chosen for further analysis. An average of 183 variants (SD=22 to the nearest integer, 
Range=145-219) were found in the 16 patients of which an average of 157 variants (SD= 20 to the nearest 
integer, Range=124-196) were common and an average of 12 variants were rare (SD=7 to the nearest 
integer, Range=4-29). On an average each cancer individual carried 13 novel variants (SD=4 to the 
nearest integer, Range=6-19) in the 159 genes. Further each cancer individual carried an average of 4 rare 
protein sequence altering mutation (SD=3 to the nearest integer, Range=0-8) and average of 2 novel 
protein sequence altering variants (SD=1.5, Range=0-5). Further every individual carried at most 4 rare 
synonymous variants and at the least no rare synonymous variants with the average being 1.6 (SD=1.5, 
Range=0-4). With regards to novel variants accounting for synonymous mutations, the average was less 
than one at 0.69 (SD=0.6, Range=0-2). The following table lists the number of variants that were 
heterozygous for all the 159 genes of interest that were either rare as per 1000 genomes reported minor 
allele frequency or were completely absent in the 1000 genomes variant data. 
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Table 7.8 Total, rare and novel nucleotide and protein sequence altering/non-altering variants 
detected for each CP+PC patient 
Patient ID Total 
number 
of het 
variant 
Number of 
common 
variants with 
MAF>0.01 (% 
of total het 
variant) 
Number of rare 
variants with 
MAF<0.01 & 
number of novel 
variants ( %of total 
het variants) 
Number of rare 
protein seq altering ( 
% of rare variants) 
& novel variants ( % 
of total novel 
variants) 
Number of rare 
synonymous ( % of 
rare variants) & 
novel synonymous 
variants (% of total 
novel variants) 
HP3 211 165 (78.2) 29 (13.7) & 17 (8.1) 8 (27.6) & 3 (17.7) 4 (13.8) & 1 (5.9) 
HP512 169 132 (78.1) 23 (13.6) & 14 (8.3) 8 (34.8) & 3 (21.4) 4 (17.4) & 1 (7.1) 
HP637 184 150 (81.5) 21 (11.4) & 13 (8.1) 8 (38.1) & 4 (30.8) 0 & 0 
NA20 201 169 (84.1) 16 (8) & 16 (7.9) 0 & 0 2 (12.5) & 0 
NA52 155 124 (80) 17 (11) & 14 (9) 4 (23.5) & 1 (7.1) 0 & 0 
NA63 214 189 (88.3) 13 (6.1) & 12 (5.6) 5 (38.5) & 2 (16.7) 4 (30.7) & 1 (8.3) 
NA232 164 146 (89) 5 (3.1) & 13 (7.9) 2 (40) & 5 (38.5) 0 & 1 (7.7) 
NA437 219 196 (89.5) 5 (2.3) & 19 (8.2) 2 (40) & 5 (26.3) 0 & 1 (5.3) 
NA823 145 135 (93.1) 4 (2.8) & 6 (4.1) 1 (25) & 1 (16.6) 1 (25) & 0 
NA1066 183 168 (91.8) 7 (3.8) & 8 (4.4) 2 (28.6) & 2 (25) 3 (43) & 1 (12.5) 
NA1265 207 181 (87.4) 14 (6.7) & 12 (5.9) 6 (42.9) & 1 (8.3) 2 (14.3) & 1 (8.3) 
PA18 189 163 (86.2) 13 (6.9) & 13 (6.9) 5 (38.5) & 2 (15.4) 0 & 1 (7.7) 
PA227 167 150 (89.8) 7 (4.2) & 10 (6) 3 (42.9) & 1 (10) 2 (28.3) & 1 (10) 
PA884 182 160 (87.9) 6 (3.3) & 16 (8.8) 0 (0) & 1 (6.25) 2 (33.3) & 2 (12.5) 
PA1238 162 144 (88.9) 10 (6.2) & 8 (4.9) 1 (10) & 2 (25) 1 (10) & 0 
PA1306 179 154 (86) 6 (3.4) & 19 (10.6) 2 (33.3) & 2 (10.5) 1 (16.7) & 0 
44
7.7 ANNOVAR GENE AND AMINO ACID CHANGE ANNOTATION RESULT FOR 
DNA REPAIR GENES IN CP-PC INDIVIDUALS 
An average of 54 variants (SD=12 to the nearest integer, Range=29-71) were found in the 11 patients of 
which an average of 50 variants (SD= 12.53 to the nearest integer, Range=25-68) were common and an 
average of 4 variants were rare (SD=2.71 to the nearest integer, Range=1-10). On an average each CP 
individual carried 2 novel variants (SD=1.3 to the nearest integer, Range=1-5) in the 159 genes. Further 
each pancreatitis individual carried an average of 1 rare protein sequence altering mutation (SD=0.5 to the 
nearest decimal, Range=0-2) and average of 0.4 novel protein sequence altering variants (SD=0.5, 
Range=0-1). Further every individual carried at most 4 rare or novel synonymous variants with the 
average being 0.9 (SD=1.3, Range=0-4). The following table lists the number of variants that were 
heterozygous for all the 159 genes of interest that were either rare as per 1000 genomes reported minor 
allele frequency or were completely absent in the 1000 genomes variant data. 
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Table 7.9 Total, rare and novel nucleotide and protein sequence altering/non-altering variants 
detected for each CP-PC patient 
Patient 
ID 
Total 
number 
of het 
variant 
Number of 
common 
variants with 
MAF>0.01 (% 
of total het 
variant) 
Number of rare 
variants with 
MAF<0.01 & 
number of novel 
variants (% of total 
het variants) 
Number of rare 
protein seq 
altering (% of 
rare variants) & 
novel variants 
(% of total 
novel variants) 
Number of rare 
synonymous (% 
of rare variants) 
& novel 
synonymous 
variants (% of 
total novel 
variants) 
HP470 71 68 (95.8) 2 (2.8) & 1 (1.4) 1 (50) & 0 0 & 1 (100) 
HP653 54 47 (87) 5 (9.3) & 2 (3.7) 1 (20) & 0 2 (40) & 0 
HP654 50 39 (78) 6 (12) & 5 (10) 1 (16.7) & 0 2 (33.3) & 2 
HP657 57 55 (96.5) 1 (1.75) & 1 (1.75) 1 (100) & 0 & 0 
NA1135 29 25 (86.2) 1 (3.45) & 3 (10.34) 1 (100) & 1 1 (100) & 0 
NA1396 51 50 (98) 0 & 1 (2) 0 & 0 0 & 0 
NA1499 71 65 (91.6) 3 (4.2) & 3 (4.2) 1 (33.3) & 0 2 (66.6) & 0 
NA1501 56 52 (92.9) 2 (3.6) & 2 (3.6) 2 (100) & 0 0  & 0 
NA324 51 48 (94.1) 0 & 3 (5.9) 0 & 1(33.3) 0 & 0 
NA6600 60 55 (91.7) 4 (6.7) & 1 (1.7) 1 (25) & 1 0 & 0 
NA992 40 39 (97.5) 0 & 1 (2.5) 0 & 0 0 & 0 
7.8 RELATIVE FREQUENCY OF PATHWAYS MOST COMMONLY DISRUPTED IN 
CP+PC AND CP-PC INDIVIDUALS 
Multiple DNA repair mechanisms are known to be involved in cellular processes and multiple genes 
involved in DNA repair have been shown to be involved in causation of PC. Thus we sought to determine 
that is a there a specific DNA repair pathway that is more frequently mutated in CP+PC individuals as 
compared to CP-PC individuals. Following table shows the rare and novel variant count of the previously 
stated DNA repair pathways under the shortlist of genes in the 16 CP+PC and the 11 CP-PC individuals. 
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Table 7.10 Rare, novel, and total variant count stratified by DNA repair pathway for first 8 CP+PC 
individuals. [Legend: rare, novel (sum of rare and novel variants)] 
Pathway wise 
rare/novel variant 
count as per 
1000genomes MAF 
HP 
3 
HP 
5
1
2
HP 
6
3
7
NA 
2
0
NA 
5
2
NA 
6
3
NA 
2
3
2
NA 
4
3
7
BER 4,3 
(7) 
4,1 
(5) 
1,0 
(1) 
1,2 
(3) 
1,1 
(2) 
1,1 
(2) 
0,2 
(2) 
Conserved DDR 6,4 
(10) 
0,2 
(2) 
1,1 
(2) 
Direct Reversal of 
Damage 
1,0 
(1) 
1,0 
(1) 
DNA Pol 6,1 
(7) 
4,3 
(7) 
5,4 
(9) 
1,1 
(2) 
3,1 
(4) 
2,1 
(3) 
1,0 
(1) 
Editing and 
performing 
1,1 
(2) 
0,1 
(1) 
0,1 
(1) 
Fanconi anemia 4,5 
(9) 
3,1 
(4) 
1,0 
(1) 
2,1 
(3) 
1,0 
(1) 
0,1 
(1) 
2,0 
(2) 
Genes def in disease 2,0 
(2) 
1,1 
(2) 
0,1 
(1) 
0,1 
(1) 
1,0 
(1) 
Homologous 
recombination 
6,3 
(9) 
5,5 
(10) 
9,8 
(17) 
5,5 
(10) 
2,1 
(3) 
2,3 
(5) 
0,3 
(3) 
0, 12 
(12) 
Mismatch repair 3,0 
(3) 
2,0 
(2) 
1,1 
(2) 
2,0 
(2) 
0,1 
(1) 
Modulation of 
nucleotide pool 
1,1 
(2) 
NER related 1,0 
(1) 
1,2 
(3) 
0,1 
(1) 
1,0 
(1) 
0,1 
(1) 
NHEJ 1,0 
(1) 
1,1 
(2) 
1,0 
(1) 
NER 2,2 
(4) 
3,2 
(5) 
3,2 
(5) 
2,2 
(4) 
1,3 
(4) 
2,2 
(4) 
0,2 
(2) 
2,3 
(5) 
Other suspected 
genes 
2,2 
(4) 
2,1 
(3) 
1,2 
(3) 
0,1 
(1) 
1,0 
(1) 
1,1 
(2) 
RAD6 pathway 1,0 
(1) 
0,1 
(1) 
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T able 7.11: Rare, novel, and total variant count stratified by DNA repair pathway for remaining 8 CP
+PC individuals. [Legend: rare, novel (sum of rare and novel variants)] 
Pathway wise 
rare/novel variant 
count as per 
1000genomes MAF 
NA 
8
2
3
NA 
1
0
6
6 
NA 
1
2
6
5
PA 
1
8
PA 
2
2
7
PA 
8
8
4
PA 
1
2
3
8
PA 
1
3
0
6
BER 2,1 
(3) 
0,2 
(2) 
1,3 
(4) 
1,3 
(4) 
4,1 
 (5) 
Conserved DDR 1,0 
(1) 
1,2 
(3) 
1,2 
(3) 
0,1 
(1) 
0,2 
(2) 
DNA Polymerases 1,1 
(2) 
2,2 
(4) 
2,1 
(3) 
2,0 
(2) 
3,1 
(4) 
2,1 
(3) 
4,0 
(4) 
0,1 
(1) 
Editing and perform 
endonuclease 
0,2 
(2) 
Fanconi anemia 0,1 
(1) 
1,0 
(1) 
3,1 
(4) 
1,0 
(1) 
0,4 
(4) 
2,0 
(2) 
Genes def in disease 1,1 
(2) 
Homologous 
recombination 
0,1 
(1) 
1,3 
(4) 
3,2 
(5) 
2,4 
(6) 
1,2 
(3) 
0,1 
(1) 
1,2 (3) 1,9 
(10) 
Mismatch repair 2,0 
(2) 
4,1 
(5) 
1,0 
(1) 
2,0 
 (2) 
0,1 
(1) 
1,2 
(3) 
Modulation of 
nucleotide pool 
0,1 
(1) 
NER related 1,0 
(1) 
0,1 
(1) 
NHEJ 1,1 
(2) 
1,3 
(4) 
0,3 
 (3) 
0,1 
(1) 
1,3 
 (4) 
0,1 
 (1) 
0,2 
 (2) 
NER 1,0 
(1) 
2,4 
(6) 
2,0 
(2) 
0,1 
(1) 
0,3 
(3) 
0,2 
(2) 
1,3 
(4) 
Other suspected 
genes 
1,1 
 (2) 
RAD6 pathway 0,1 
(1) 
1,0 
(1) 
DNA protein cross-
link 
1,0 
(1) 
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Table 7.12 Rare and novel variant count Stratified by DNA repair pathway for CP-PC 
individuals [legend: rare, novel (sum of rare and novel variants)] 
Pathway wise 
rare/novel variant 
count as per 
1000genomes 
MAF 
HP 
4
7
0
HP 
6
5
3
HP 
6
5
4
HP 
6
5
7
NA 
1
1
3
5
NA 
1
3
9
6
NA 
1
4
9
9
N
A
1 
5 
0 
1 
NA 
3
2
4
NA 
6
6
0
0
NA 
9
9
2
BER 1,0 
(1) 
0,1 
(1) 
2,0 
(2) 
1,0 
(1) 
1,0 
(1) 
Conserved DDR 1,0 
(1) 
DNA 
Polymerases 
2,0 
(2) 
2,1 
(3) 
0,1 
(1) 
0,1 
(1) 
0,1 
(1) 
2,0 
(2) 
0,1 
(1) 
Fanconi Anemia 0,2 
(2) 
0,3 
(3) 
0,1 
(1) 
0,1 
(1) 
Homologous 
Recombination 
0,1 
(1) 
1,0 
(1) 
0,1 
(1) 
Mismatch Repair 1,0 
(1) 
1,1 
(2) 
0,1 
(1) 
NER Related 3,0 
(3) 
0,1 
(1) 
1,0 
(1) 
0,1 
(1) 
NHEJ 0,1 
(1) 
1,0 
(1) 
Nucleotide 
Excision Repair 
2,0 
(2) 
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7.9 NUMBER OF RARE NON-SYNONYMOUS PROTEIN SEQUENCE ALTERING 
VARIANTS DETECTED IN DNA REPAIR GENES OF 16 CP+PC INDIVIDUALS 
Of the 16 CP+PC individuals, 14 patients carried at least one rare non-synonymous mutation while 15 
patients carried at least one novel non-synonymous mutation. The average number of rare non-
synonymous mutation in CP+PC individuals were 4 to the nearest integer (SD=2.8 Range=0-8) and an 
average of 2 (SD=1.5 Range=0-4) to the nearest integer of rare synonymous variants. The average 
number of novel non-synonymous mutations was in the PC individuals was 2 to the nearest integer 
(SD=1.5, Range=0-5) and the average of novel synonymous mutations was less than one at 0.7 to the 
nearest integer (SD=0.6, Range=0-2). The following table lists the number of rare and novel non-
synonymous and synonymous variants found in each of the cancer individuals. 
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Table 7.13 Number of rare and novel protein sequence altering variants for each CP+PC individual 
Patient ID Number of rare/novel protein 
sequence altering variants 
Number of rare/novel 
synonymous variants 
HP3 5 / 3 3 / 1 
HP512 4 / 4 2 / 1 
HP637 3 /5 0 / 0 
NA20 0 / 0 1/ 0 
NA52 2 / 2 0 / 0 
NA63 5 / 2 3 / 1 
NA232 2 / 5 0 / 1 
NA437 2 / 5 0 / 1 
NA823 1 / 1 1 / 0 
NA1066 2 / 2 3 / 1 
NA1265 6 / 1 2 / 1 
PA18 5 / 2 0 / 1 
PA227 3 / 1 2 / 1 
PA884 0 / 1 2 / 2 
PA1238 1 / 2 1 / 0 
PA1306 2 / 2 0 / 1 
7.10 NUMBER OF RARE NON-SYNONYMOUS PROTEIN SEQUENCE 
ALTERING VARIANTS DETECTED IN DNA REPAIR GENES OF 11 CP-PC 
INDIVIDUALS 
Of the 11 CP-PC individuals, 9 patients carried at least one rare non-synonymous mutation while 4 
patients carried at least one novel non-synonymous mutation. The average number of rare non-
synonymous mutation in CP-PC individuals was 1 to the nearest integer (SD=0.54 Range=0-2) and an 
average of 0.72 (SD=0.90 Range=0-2) to the nearest integer of rare synonymous variants. The average 
number of novel non-synonymous mutations in the CP individuals was 0.3 to the nearest decimal point 
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(SD=0.5, Range=0-1) and the average of novel synonymous mutations was less than one at 0.2 to the 
nearest decimal point (SD=0.6, Range=0-2). The following table lists the number of rare and novel non-
synonymous and synonymous variants found in each of the chronic pancreatitis individuals. 
Table 7.14 Number of rare and novel protein sequence altering variants for each CP-PC individual 
Patient ID Number of rare non-
synonymous/novel non-
synonymous variants 
Number of rare 
synonymous/novel 
synonymous variants 
HP470 1/0 1/0 
HP653 1/0 2/0 
HP654 1/0 2/2 
HP657 1/1 0/0 
NA1135 1/1 1/0 
NA1396 0/0 0/0 
NA1499 1/0 2/0 
NA1501 2/0 0/0 
NA324 1/1 0/0 
NA6600 1/1 0/0 
NA992 0/0 0/0 
7.11 NOVEL GERMLINE PROTEIN SEQUENCE ALTERING MUTATIONS FOUND 
IN CP+PC INDIVIDUALS 
The rare and novel germline mutations that resulted in alteration of protein sequences in the CP+PC 
individuals are listed in the table below along with the patient ID of the individual carrying that mutation. 
Using Annovar to annotate resulted in annotation of the variant position in the transcript, the transcript 
ID, the cDNA change, amino acid change and the type of mutation. A total of 82 germline mutations that 
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altered protein sequence were found in the 16 individuals of which 38 were absent from the thousand 
genomes project and 44 were present in the thousand genomes at a minor allele frequency of 0.01 or less. 
A major issue in exome sequencing as compared to traditional Sanger sequencing is that unlike Sanger 
sequencing, exome sequencing does not have very high fidelity rates. Thus coverage data along with 
allele count of a particular variant is very important in determining whether a variant is truly present or is 
just a sequencing artifact. Of the 38 novel protein sequence altering variants, 21 were present with an 
alternative allele counting for greater than 20 reads and being present at a frequency of at least 20% in 
those reads and of the 44 rare variants, 38 were present with an alternative allele counting for greater than 
20 reads and being present at a frequency of at least 20% in those reads.  
The GERP score annotation results did not report a single mutation to have a GERP score above 
the threshold of 2 suggesting that majority of the mutations identified might not be evolutionarily 
constrained and thus not highly conserved sites.  
The table below lists all the protein sequence altering variants found in the 16 CP+PC individuals 
that were either rare as per thousand genomes minor allele frequency or were absent in thousand genomes 
variant data. 
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Table 7.15 Novel and rare germline protein sequence altering variants for HP3 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
el 
Read count for variant in 
exome seq data 
GEN1 GEN1:NM_001130009:ex
on5:c.G566A p.S189N 
2 17947886 
 
0.01 AC=43;AF=51.807;AN=
83 
POLQ POLQ:NM_199420:exon1
6:c.C4141A:p.P1381T 
3 121207637 
 
0.01 AC=24;AF=39.344;AN=
61 
POLN POLN:NM_181808:exon5:
c.C943T:p.P315S
4 2195009 
 
0.01 AC=16;AF=41.026;AN=
39 
REV3L REV3L:NM_002912:exon
13:c.G5434C:p.D1812H, 
6 111694124 
 
0.01 AC=17;AF=35.417;AN=
48 
BRCA1 BRCA1:NM_007294:exon
15:c.G4956A:p.M1652I 
BRCA1:NM_007300:exon
16:c.G5019A:p.M1673I 
BRCA1:NM_007297:exon
14:c.G4815A:p.M1605I 
BRCA1:NM_007298:exon
14:c.G1644A:p.M548I 
17 41222975 0.01 AC=31;AF=26.724;AN=
116 
MRE11A MRE11A:NM_005590:exo
n8:c.T752G:p.I251R 
11 94204833 
 
NOVEL AC=3;AF=25.0;AN=12 
 BRCA2 BRCA2:NM_000059:exon
10:c.1751_1755del:p.584_
585del 
13 32907366- 
32907370 
 
NOVEL AC=25;AF=46.296;AN=
54 
 FANCA FANCA:NM_001018112:e
xon8:c.C775A:p.P259T 
89869684 NOVEL AC=5;AF=27.778;AN=1
8 
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Table 7.16 Novel and rare germline protein sequence altering variants for HP512 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
l 
Read count for 
variant in exome 
seq data 
MSH6 MSH6:NM_000179:exon4
:c.T2633C:p.V878A 
 
2 48027755 0.01 AC=10;AF=23.25
6;AN=43 
 PMS1 PMS1:NM_000534:exon6:
c.G605A:p.R202K
2 190708712 0.01 AC=9;AF=25.714
;AN=35 
 MBD4 MBD4:NM_001276271:ex
on3:c.T1073C:p.I358T 
 
3 129155414 0.01 AC=20;AF=64.51
6;AN=31 
 PMS2 PMS2:NM_000535:exon1
1:c.A1789T:p.T597S, 
 
7 6026607 0.0046 AC=31;AF=40.78
9;AN=76 
 DCLRE1
A 
DCLRE1A:NM_00127181
6:exon2:c.T100G:p.S34A 
 
10 115612842 NOVEL AC=3;AF=23.077
;AN=13 
 EME1 EME1:NM_152463:exon2
:c.409_410insAGC:p.K13
7delinsKQ 
17 48452978 NOVEL AC=32;AF=54.23
7;AN=59 
 XRCC1 XRCC1:NM_006297:exon
17:c.A1896T:p.Q632H 
 
19 44047550 NOVEL AC=5;AF=33.333
;AN=15 
 GEN1 GEN1:NM_001130009:ex
on14:c.2518_2519del:p.84
0_840del 
2 17962997 
- 
17962998 
NOVEL AC=1;AF=2.273;
AN=44 
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Table 7.17: Novel and rare germline protein sequence altering variants for HP637 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
el 
Read count for 
variant in exome 
seq data 
ALKBH2 ALKBH2:NM_001205179:
exon3:c.G409A:p.V137M
ALKBH2:NM_001001655:
exon4:c.G608A:p.R203H 
 
12 109526189 0.01 AC=12;AF=44.44
4;AN=27 
BRCA2 BRCA2:NM_000059:exon
10:c.A1385G:p.E462G, 
 
13 32907000 NOVEL AC=7;AF=33.333;
AN=21 
 BIVM-
ERCC5,
ERCC5 
ERCC5:NM_000123:exon
4:c.G438C:p.L146F 
BIVM-
ERCC5:NM_001204425:e
xon12:c.G1800C:p.L600F, 
13 103506695 NOVEL AC=4;AF=23.529;
AN=17 
FANCM FANCM:NM_020937:exon
9:c.1490_1491insA:p.S497
fs, 
14 45628392 NOVEL AC=10;AF=31.25;
AN=32 
FANCM FANCM:NM_020937:exon
20:c.A5224G:p.I1742V, 
 
14 45658449 0.0041 AC=15;AF=30.61
2;AN=49 
 MLH3 MLH3:NM_001040108:ex
on2:c.T2896C:p.S966P 
 
14 75513463 0.01 AC=27;AF=47.36
8;AN=57 
 ERCC4 ERCC4:NM_005236:exon
11:c.T2117C:p.I706T, 
 
16 14041570 NOVEL AC=35;AF=47.29
7;AN=74 
 EME1 EME1:NM_152463:exon2:
c.409_410insAGC:p.K137
delinsKQ 
EME1:NM_001166131:ex
on2:c.409_410insAGC:p.K
137delinsKQ, 
17 48452978 NOVEL AC=19;AF=26.02
7;AN=73 
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Table 7.18 Novel and rare germline protein sequence altering variants for NA52 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
l 
Read count for 
variant in exome 
seq data 
GEN1 GEN1:NM_001130009:ex
on14:c.C2692T:p.R898C 
 
2 17963171 0.01 AC=27;AF=37.5;
AN=72 
 NUDT1 NUDT1: 
NP_945192.1:c.505C>A; 
Leu169Met 
7 2290601 NOVEL AC=14;AF=35.0;
AN=40 
 PRKDC PRKDC: NP_001075109 
c340C>T P1154S 
 
8 48811034 NOVEL AC=3;AF=27.273
;AN=11 
 RECQL5 RECQL5:NM_004259:exo
n15:c.G1883A:p.S628N, 
17 73625852 0.01 AC=5;AF=38.462
;AN=13 
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Table 7.19 Novel and rare germline protein sequence altering variants for NA63 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
el 
Read count for 
variant in exome 
seq data 
ERCC5 ERCC5:NM_000123:exon1
2:c.A2636G:p.N879S 
BIVMERCC5:NM_001204
425:exon20:c.A3998G:p.N
1333S, 
 
13 103520565 0.01 AC=18;AF=58.06
5;AN=31 
FANCM FANCM:NM_020937:exon
1:c.G171C:p.L57F, 
14 45605405 
 
0.0009 
 
AC=15;AF=45.45
5;AN=33 
BRCA1 BRCA1:NM_007294:exon
10:c.A4039G:p.R1347G 
BRCA1:NM_007297:exon
9:c.A3898G:p.R1300G 
 
17 41243509 0.0009 AC=32;AF=45.07
;AN=71 
PMS2 PMS2:NM_000535:exon11
:c.G1688T:p.R563L 
7 6026708 
 
0.01 
 
AC=42;AF=41.17
6;AN=102 
PRKDC PRKDC: 
NP_001075109.1:p.[Pro695
Ser]; PRKDC: 
NP_008835.5:p.[Pro695Ser
] 
8 48841708 0.01 AC=11;AF=35.48
4;AN=31 
ATM ATM:NM_000051:exon18:
c.2807delT:p.L936fs,
11 108139305 
 
NOVEL AC=4;AF=30.769
;AN=13 
 CETN2 CETN2:NM_004344:exon2
:c.92_93insG:p.Q31fs, 
X 151998216 NOVEL AC=3;AF=30.0;A
N=10 
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Table 7.20 Novel and rare germline protein sequence altering variants for NA232 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
el 
Read count for 
variant in exome 
seq data 
POLE POLE:NM_006231:exon8:
c.G776A:p.R259H
12 133253974 
 
0.01 
 
AC=45;AF=40.90
9;AN=110 
POLH POLH:NM_006502:exon1
1:c.A1783G:p.M595V, 
6 43581935 
 
0.01 
 
AC=39;AF=37.5;
AN=104 
GEN1 GEN1:NM_001130009:ex
on14:c.2516_2517del:p.83
9_839del 
2 17962995 NOVEL AC=1;AF=1.587;
AN=63 
 WRN WRN:NM_000553:exon2
5:c.A3101T:p.Y1034F 
 
8 30999079 NOVEL AC=18;AF=27.69
2;AN=65 
 RAD54B RAD54B:NM_012415:exo
n14:c.T2363C:p.L788P 
RAD54B:NM_001205263
:exon12:c.T1811C:p.L604
P, 
8 95390560 NOVEL AC=6;AF=24.0;A
N=25 
TDG TDG:NM_003211:exon3:c
.286_287insA:p.E96fs 
12 104373728 
 
NOVEL AC=12;AF=54.54
5;AN=22 
 EME1 EME1:NM_001166131:ex
on2:c.409_410insAGC:p.
K137delinsKQ 
17 48452978 NOVEL AC=35;AF=47.29
7;AN=74 
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Table 7.21 Novel and rare germline protein sequence altering variants for NA437 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
el 
Read count for 
variant in exome 
seq data 
ATM ATM:NM_000051:exon31
:c.T4709C:p.V1570A, 
11 108164137 
 
0.0005 
 
AC=17;AF=35.41
7;AN=48 
ERCC5 ERCC5:NM_000123:exon
12:c.A2636G:p.N879S 
BIVM-
ERCC5:NM_001204425:e
xon20:c.A3998G:p.N1333
S 
13 103520565 0.01 AC=15;AF=29.41
2;AN=51 
SMC6 SMC6:NM_001142286:ex
on5:c.G308A:p.G103E 
2 17919524 
 
NOVEL AC=4;AF=25.0A
N=16 
GEN1 GEN1:NM_001130009:ex
on14:c.2518delT:p.L840X 
2 17962997 
 
NOVEL AC=1;AF=1.639;
AN=61 
GEN1 GEN1:NM_001130009:ex
on14:c.2515_2516del:p.83
9_839del 
2 17962994 NOVEL AC=1;AF=1.639;
AN=61 
 EME1 EME1:NM_001166131:ex
on2:c.409_410insAGC:p.
K137delinsKQ 
17 48452978 NOVEL AC=19;AF=21.59
1;AN=88 
 EME1 EME1:NM_001166131:ex
on7:c.G1306A:p.A436T 
17 48456849 NOVEL AC=32;AF=36.78
2;AN=87 
Table 7.22 Novel and rare germline protein sequence altering variants for NA823 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
Read count for 
variant in exome 
seq data
REV3L REV3L:NM_002912:exon
13:c.A4004G:p.N1335S 
6 111695554 
 
0.0005 
 
AC=13;AF=46.42
9;AN=28 
EME1 EME1:NM_152463:exon2
:c.409_410insAGC:p.K13
7delinsKQ 
17 48452978 NOVEL AC=21;AF=28.76
7;AN=73 
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Table 7.23 Novel and rare germline protein sequence altering variants for NA1066 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
el 
Read count for 
variant in exome 
seq data 
MRE11A MRE11A:NM_005590:ex
on13:c.C1475A:p.A492D 
11 94192599 
 
0.0018 
 
AC=13;AF=48.14
8;AN=27 
FANCA FANCA:NM_000135:exo
n35:c.C3427G:p.L1143V, 
16 89813078 
 
0.0009 
 
AC=17;AF=39.53
5;AN=43 
POLL POLL:NM_001174084:ex
on9:c.G1492A:p.E498K 
POLL:NM_001174085:ex
on9:c.G1216A:p.E406K, 
 
10 103339446 NOVEL AC=15;AF=46.87
5;AN=32 
POLE POLE:NM_006231:exon1
2:c.1171_1173del:p.391_3
91delTT 
12 133252037- 
133252039 
NOVEL AC=7;AF=31.818
;AN=22 
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Table 7.24 Novel and rare germline protein sequence altering variants for NA1265 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
l 
Read count for 
variant in exome 
seq data 
BRCA2 BRCA2:NM_000059:exon
11:c.C5744T:p.T1915M, 
13 32914236 0.01 AC=9;AF=50.0;A
N=18 
APEX1 APEX1:NM_080648:exon
3:c.G153C:p.Q51H 
14 20924167 0.01 AC=4;AF=36.364
;AN=11 
FANCI FANCI:NM_001113378:e
xon18:c.C1813T:p.L605F 
15 89828441 0.0018 AC=17;AF=36.17
;AN=47 
POLG POLG:NM_001126131:ex
on16:c.A2492G:p.Y831C 
15 89865073 0.0018 AC=4;AF=28.571
;AN=14 
GEN1 GEN1:NM_001130009:ex
on14:c.T2619G:p.S873R 
2 17963098 0.01 AC=14;AF=29.16
7;AN=48 
GEN1 GEN1:NM_001130009:ex
on14:c.C2692T:p.R898C 
2 17963171 0.01 AC=37;AF=41.57
3;AN=89 
MUTYH MUTYH:NM_001048174:
exon8:c.G566A:p.R189H 
MUTYH:NM_001048172:
exon8:c.G569A:p.R190H 
MUTYH:NM_001128425:
exon8:c.G650A:p.R217H 
MUTYH:NM_001048171:
exon8:c.G608A:p.R203H 
1 45798286 NOVEL AC=5;AF=31.25;
AN=16 
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Table 7.25 Novel and rare germline protein sequence altering variants for PA18 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
l 
Read count for 
variant in exome 
seq data 
MLH3 MLH3:NM_001040108:ex
on2:c.G1870C:p.E624Q 
 
14 75514489 0.01 AC=21;AF=53.84
6;AN=39 
BRCA1 BRCA1:NM_007300:exon
10:c.G3119A:p.S1040N 
BRCA1:NM_007297:exon
9:c.G2978A:p.S993N 
17 41244429 0.01 AC=18;AF=47.36
8;AN=38 
POLQ POLQ:NM_199420:exon1
6:c.C4141A:p.P1381T, 
3 121207637 0.01 AC=24;AF=64.86
5;AN=37 
MLH1 MLH1:NM_001258274:ex
on17:c.A1129G:p.K377E
MLH1:NM_001258271:ex
on16:c.A1852G:p.K618E 
3 37089130 0.0041 AC=23;AF=46.0;
AN=50 
MLH1 MLH1:NM_001258274:ex
on17:c.A1130C:p.K377T
MLH1:NM_001258271:ex
on16:c.A1853C:p.K618T 
3 37089131 0.0041 AC=23;AF=46.0;
AN=50 
RECQL5 RECQL5:NM_004259:exo
n16:c.C2217G:p.S739R 
17 73625286 
 
NOVEL AC=3;AF=27.273
;AN=11 
EME1 EME1:NM_152463:exon2
:c.409_410insAGC:p.K13
7delinsKQ 
17 48452978 NOVEL AC=13;AF=54.16
7;AN=24 
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Table 7.26 Novel and rare germline protein sequence altering variants for PA227 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nove
l 
Read count for 
variant in exome seq 
data 
FANCM FANCM:NM_020937:exon2
0:c.A5224G:p.I1742V, 
 
14 45658449 0.0041 AC=37;AF=43.023;A
N=86 
 MLH3 MLH3:NM_001040108:exon
2:c.T2896C:p.S966P 
 
14 75513463 0.01 AC=24;AF=34.286;A
N=70 
 POLG POLG:NM_001126131:exon
10:c.C1760T:p.P587L 
 
15 89868870 0.0009 AC=3;AF=30.0;AN=
10 
 EME1 EME1:NM_152463:exon2:c.
409_410insAGC:p.K137deli
nsKQ 
17 48452978 NOVEL AC=16;AF=32.0;AN
=50 
Table 7.27 Novel and rare germline protein sequence altering variants for PA884 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
Read count for 
variant in exome 
seq data
POLI POLI:NM_007195:exon9:
c.A1255G:p.M419V
18 51818259 NOVEL AC=6;AF=35.294
;AN=17 
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Table 7.28 Novel and rare germline protein sequence altering variants for PA1238 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
l 
Read count for 
variant in exome 
seq data 
REV3L REV3L:NM_002912:exon
13:c.G5434C:p.D1812H 
 
6 111694124 0.01 AC=27;AF=44.26
2;AN=61 
 GTF2H4 GTF2H4:NM_001517:exo
n2:c.T46A:p.C16S 
 
6 30876859 NOVEL AC=6;AF=25.0;A
N=24 
BLM BLM:NM_000057:exon7:
c.A1538T:p.K513I,
15 91304141 NOVEL AC=10;AF=28.57
1;AN=35 
Table 7.29 Novel and rare germline protein sequence altering variants for PA1306 
Gene Transcript/cDNA/exon 
no/amino acid change 
Chr 
no 
Genomic co-
ordinate 
Thousand 
genome 
MAF/Nov
l 
Read count for variant in 
exome seq data 
MUS81 MUS81:NM_025128:exon
10:c.C1048T:p.R350W 
 
11 65631361 0.01 AC=16;AF=43.243;AN=3
7 
 FANCC FANCC:NM_000136:exo
n7:c.A584T:p.D195V 
 
9 97912307 0.0046 AC=9;AF=75.0;AN=12 
ATR ATR:NM_001184:exon8:c
.T1878G:p.D626E 
 
3 142277473 NOVEL AC=59;AF=47.967;AN=1
23 
 EME1 EME1:NM_001166131:ex
on2:c.409_410insAGC:p.
K137delinsKQ 
17 48452978 NOVEL AC=13;AF=25.0;AN=52 
PRKDC PRKDC: 
NP_001075109.1:p.[*2393
fs]; 
NP_008835.5:p.[*2393fs] 
8 48761817 NOVEL AC=5;AF=29.412;AN=17 
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7.12 TEST OF SIGNIFICANCE OF DIFFERENCE OF FREQUENCY OF OVERALL 
TYPE OF MUTATION BETWEEN CP+PC INDIVIDUALS AND CP-PC INDIVIDUALS. 
Following the classification of the variants as rare or common according to minor allele frequency, the 
Mann-Whitney U test was carried out to see if there is a difference in the common or rare or rare and 
novel synonymous and protein sequence altering variants between CP+PC and CP-PC individuals. 
Table 7.30 Mann-Whitney results for common, rare and synonymous variants for comparing CP
+PC and CP-PC individuals. 
Category of mutations Mann-Whitney p value for CP+PC vs. CP-PC 
individuals 
Common variants at MAF>0.01 in 156 DNA 
repair genes 
p<0.0001 
Rare variants at MAF<=0.01 and novel 
variants in 156 DNA repair genes 
p<0.0001 
Synonymous rare and novel variants p=0.1372 
Protein sequence altering rare and novel 
variants  
p=0.0003 
7. 13 RARE VARIANT BURDEN TEST OF DNA REPAIR PATHWAYS
The ANOVA test of normality showed that the normality of residual assumption was violated for most of 
the pathway comparisons of CP+PC and CP-PC individuals. For those pathways or comparisons types 
failing the normality assumption, the non-parametric Mann-Whitney test was used to compare the rare 
variant load and rank the most frequently mutated DNA repair pathways in CP+PC individuals as 
compared to CP-PC individuals. The following table lists the Mann-Whitney test p values ranked from 
the most significant to the least significant. 
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Table 7.31 Mann Whitney test for comparison of rare and novel variants in CP+PC vs. CP-PC 
DNA repair pathway Mann Whitney test p 
l  
Rank as the most significant 
Homologous recombination 2.14*10^-6 1 
Nucleotide excision repair 5.13*10^-6 2 
DNA polymerases 7.89*10^-4 3 
Base excision repair 3.9*10^-3 4 
Non-homologous end joining 8.6*10^-3 5 
Fanconi Anemia 1.06*10^-2 6 
Mismatch repair 1.11*10^-2 7 
Conserved DNA damage repair 1.25*10^-2 8 
Other suspected genes 1.29*10^-2 9 
Genes defective in disease 2.71*10^-2 10 
Editing and performing 
d l  
0.1225 11 
RAD6 pathway 0.1225 11 
Direct reversal of damage 0.3419 13 
Modulation of nucleotide pool 0.3419 13 
Nucleotide excision repair 
l d 
0.4762 15 
Repair of DNA protein cross 0.5926 16 
The Mann-Whitney test results showed that among the major DNA repair pathways, homologous 
recombination and nucleotide excision repair were the most frequently carriers of novel and rare germline 
mutations followed by the DNA polymerases and base excision repair and finally the non-homologous 
end joining pathway.  
A major factor that may have propelled the homologous recombination pathway to be most 
significant is the fact that it has the second highest number of genes to be involved in DNA repair 
pathways at 21 and some of the genes could be highly polymorphic as well coupled with the fact that non-
homologous end joining type of DNA repair pathway was also fairly significant suggesting DNA double 
strand break repair might be one of the most frequently mutated pathways in the germline DNA  of the 
repair genes of PC patients as compared to non cancerous patients.  
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7.14 RANKING OF THE MOST FREQUENTLY MUTATED GENES IN THE DNA 
REPAIR PATHWAYS 
A major objective of this study was to identify which genes were most frequently mutated in the CP+PC 
individuals that would ideally serve as potential gene to be screened in a high risk population for risk of 
PC. With PC being a disease with a fairly poor prognosis, identifying high risk genes could be useful for a 
potential genetic screening in high risk patients such as HP or CP for the future. The following table lists 
the most frequently mutated genes in the PC patients either as carriers of novel variants or rare variants at 
a MAF<0.01. 
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Table 7.32 List of most frequently mutated genes that were either rare or novel for each CP+PC 
individual 
Patient 
ID 
Most frequently mutated gene carrying rare 
variants 
Most frequently mutated gene carrying novel 
variants 
HP3 PARP1 (3) PARP1, FANCM (3) 
HP512 GEN1, REV3L, XRCC1 (2) GEN1, REV3L (2) 
HP637 RAD52 (7), FANCM (2) RAD52 (6) 
NA20 RAD52 (4), PAPD7 (3), RAD23B (2) RAD52 (4) 
NA52 RRM2 , TP53 (2) GTF2H5 (2) 
NA63 ERCC5 (2) GEN1, CHEK2 (2) 
NA232 ATR, POLH. MGMT, POLE, RAD52B (1) RAD23B (2) 
NA437 FANCA, POLK, FANCC, ATM, ERCC5, 
MNAT1 (1) 
RAD52 (6) 
NA823 ATR, XRCC4, REV3L, RAD52B (1) ENDOV (2) 
NA1066 MSH6, RAD17, MSH5, MRE11A, POLG, 
FANCA, POLM (1) 
GEN1, SMC6, NUDT1, POLL, RAD9A, 
RRM1, POLE, RAD51B (1) 
NA1265 GEN1 (2) RAD23B (2) 
PA18 MLH1 (2) APEX1 (2), TP53 (2) 
PA227 PARP1, POLS, POLM, BRCA2, FANCM, 
MLH3, POLG (1) 
GEN1, SMC6, NUDT1, POLL, RAD9A, 
RRM1, POLE, RAD51B (1) 
PA884 XRCC5, POLK, MSH3, MLH3,APEX1, 
POLD1 (1) 
FANCD2, SIRT1, APEX1 (2) 
PA1238 MUTYH, REV1, REV3L, POLB,WRN, 
MUS81, POLG, PNKP, XRCC1, APEX2 (1) 
OGG1, GTF2H4, MSH5, XRCC2, PRKDC, 
RAD23B, RAD52, BLM (1) 
PA1306 UBE2V2 (1), FANCC, MUS81, GTF2H1, 
MLH3, FANCA (1) 
RAD52 (6) 
As the table above shows, that there was no one single common gene or genes that carried rare or 
novel variants in all CP+PC individuals thus suggesting that depending on the DNA damage type, 
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multiple DNA repair pathways are involved in the repair of damaged DNA in the pancreas and statistical 
testing results of pathways tested before using Mann-Whitney test to find the most significantly mutated 
pathway need to be followed up in larger exome sequencing studies to see if this significance remains 
even after the patient number increases. Further resequencing based studies in larger PC cohorts to 
determine the genotype status of the potentially deleterious mutations detected here will help identify the 
significance of that gene in PC individuals who had CP.  
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8.0 DISCUSSION 
In this study we report 59 out of a total of 82 protein sequence altering germline mutations in 16 PC 
patients who had CP before developing cancer that were present at an allele count of greater than 20 with 
coverage of at least 31. A relatively high coverage and allele count was considered due to the fact that aim 
of the study was to identify germline mutations which should be a moderately high coverage for a variant 
to be considered as a true variant and not a sequencing artifact. 
With the initial hypothesis being that CP+PC had a higher genetic risk of PC as compared to non-
cancerous CP individuals, a burden test in the form of Mann-Whitney U test was used to identify if the 
DNA repair genes carried a greater load of rare or common variants in the genes of interest in CP+PC 
individuals as compared to CP-PC individuals. The Mann-Whitney U test suggested that CP+PC 
individuals carry a greater load of both common genetic variants (p<0.0001) and rare genetic variants 
(p=0.0021) as well significantly higher proportion of protein sequence altering rare genetic variants 
(1.4*10^-3). This proves our initial hypothesis to significant extent with certain limitations including an 
incapability to gauge the effect of intronic and UTR variants that do not affect protein sequence. However 
UTR variants are known to be involved in post-transcriptional regulation of gene expression including 
transport of mRNA out of nucleus as well as determination of translational efficiency and subcellular 
localization. Thus although the CP+PC patient NA20 did not carry any protein sequence altering variants, 
it could be that the improper functioning of the DNA repair genes in this individual was related to the 
presence of the UTR variants that interfered with the regulation of expression of a vital gene thus 
predisposing this individual to the risk of PC. It is difficult to estimate the effect of common variants as 
the variant frequency above the threshold of 0.01 has significant variation with minor allele frequency 
ranging from 0.02-1. However with pancreatic cancer being a fairly rare disease and having a worse 
prognosis, fairly common variants could be ruled out as susceptible highly penetrative mutations for 
disease in a high risk group such as chronic pancreatitis individuals. Thus rare variants and novel variants 
of DNA repair pathways were the focus of further analysis. 
With multiple pathways are involved in DNA repair, one of our hypotheses sought to determine if 
any specific DNA repair pathway/s were more frequently disrupted in the cancer individuals as compared 
to the non-cancer individuals.  We found homologous recombination and nucleotide excision repair being 
the most frequently carriers of novel and rare germline mutations followed by the DNA polymerases and 
base excision repair and finally the non-homologous end joining pathway. A major factor contributing to 
this observation could be the fact that of all the DNA repair pathways, homologous recombination and 
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nucleotide excision repair has the highest number of genes at 21 and 23 respectively. No particular gene 
dominated in terms of having the highest number of rare or novel mutations or being common in all 
cancer individuals suggesting that with DNA repair protein forming complexes to repair damaged DNA, 
disruption in the sequence of any particular gene could affect the binding of the overall complex and thus 
interfere with repair of damaged DNA. 
Non-synonymous and other protein sequence altering mutations are to known to have the 
potentiality to interfere with the normal function of a protein and since in the majority of the DNA repair 
pathways, multi protein complexes act to repair damaged DNA, disruption in normal function of one 
protein could interfere with the functioning of a protein complex thus interfering with the overall 
functioning of the DNA repair pathway. Thus it was sought to determine if there is greater proportion of 
novel and rare protein sequence altering variants in the DNA repair genes of the CP+PC individuals as 
compared to the CP-PC individuals and it was found that protein sequences altering mutations were 
present at a significantly greater average in CP+PC individuals as compared to CP-PC individuals. Indeed 
15 out of 16 CP+PC patient carried at least one rare or novel protein sequence altering mutation at an 
average of 4 rare and 2 novel protein sequence altering mutations while although 9 out of 11 CP-PC 
patients carried at least one rare or novel germline protein sequence altering variants, the average was 
much lower at 1 rare and 0.4 novel protein sequence altering mutations. The Mann-Whitney U test results 
supported this finding with p value reported to be 0.0003 for comparison of number of protein sequence 
altering variants between the two groups of patients. With coverage being a major issue in exome 
sequencing when the non-synonymous variant comparison was done only variants with coverage of at 
least 20 and the non-reference allele being present in at least 4 reads, the Mann-Whitney test still reported 
a high p value of 0.0001 thus proving that rare and novel protein sequence altering variants are present at 
a greater proportion in cancer individuals and possibly loss of function of these variants give the greater 
risk of cancer to the CP+PC individuals as compared to the CP-PC individuals.   
Among the genes that have been found to be involved in determining PC survival or prognosis or 
been suspected to have some role in the disease via genetic association studies, only 3 genes, namely 
ERCC4, ATM and MLH1 were found to carry germline mutations in the CP+PC individuals thus 
demanding significant further attention. Further none of the previous mutations identified in PC mutation 
screening studies were present in any of the CP+PC individuals suggesting that potentially CP+PC 
individuals have a different genetic risk as compared to PC individuals who did not have CP. 
Multiple genes have been found to be involved in PC causation via genome-wide association 
studies and none of the genes found to be significant at the genome-wide level in these studies were 
found to carry a high risk variant. This point to the conclusion that common variants in DNA repair 
genes are might not explain the high genetic risk that CP patients that develop PC have and helps to 
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rationalize and further justify the rare and novel variant approach adapted over here. Follow up study that 
focuses on sequencing the tumor DNA of the CP+PC individuals to determine genotype status of the 
mutations detected in this study would help increase the susceptibility that these mutations are the risk 
variants that predispose CP individuals to risk of PC. It would also be advisable to follow up these 
mutations in PC individuals in general by genotyping matched normal and tumor DNA to determine 
how significant an effect these variants have in general PC population and finally functional studies 
that focus on creating mutant constructs with these mutations to compare the expression level of these 
genes to PC cell line expression of that particular mutant construct could help deduce the effect of 
these mutations at the cellular level. Comparing tissue histologies of pancreas cell line with these 
mutations and pancreatic cancer cell line will also help identify if these mutations truly have an effect 
at the normal functioning of the gene at the cellular level. 
A major confounding factor that reduces the significance of the results found in this study is the 
significant difference in mean age of the two groups of patients. However the fact that germline mutations 
that have been investigated here do not change over time eliminates age as a confounding variable. 
Further the potentiality remains that some of these non cancerous patients may go on to develop PC in the 
future biasing the test towards null hypothesis of no significant difference in age and the effects further 
investigated over here could possibly be the same or even larger if the comparison group was confirmed 
cancer free older participants.   
Although a relatively low number of patients were included in this study, the p values for the 
pathway based burden test as well the burden test of difference in number of non-synonymous variants 
were highly significant between the two groups of patients and thus are worthy of follow up in a exome 
sequencing study with a greater number of patients as well as in a larger PC patient cohort to see if the 
potentially high risk variants identified here are a risk in a general cohort of PC patients or not.  Hence the 
findings of this pilot study should be treated with discretion and follow up studies are highly vital to 
establish the conclusions derived from this study as being generally applicable to all at risk PC patient 
cohorts. Further exome sequencing does not take into account epigenetic factors that could affect the 
expression of a gene regardless of sequence differences resulting in exclusion of one major factor that 
controls expression of cancer genes. It also worthwhile to note that with the advent of RNA sequencing, 
exome data is not always found to correlate with RNA sequencing data and hence follow up RNA 
sequencing studies would also be highly helpful. Finally factors like microRNA that might direct 
transcript degradation or control gene expression in cancer cells is not accounted by exome sequencing 
studies coupled with fact that evidence exists for RNA editing in tumors where single nucleotide variants 
are introduced into transcribed RNAs that is not present in exons of genomic DNA leads to the cautionary 
treatment of these findings until backed up by multiple validation studies. 
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APPENDIX A: LIST OF GERMLINE MUTATIONS IDENTIFIED IN PREVIOUS STUDIES 
Table A1: Germline mutation among 159 genes of interest identified in previous studies
Gene Mutation 
ATM c.8266A>AT p.K2756X
c.170G>GA p.W57X
c.3214G>GT p.E1072X
c.6095G>GA p.R2032K
IVS41-1G>GT 
c.3801delG
BRCA1 c.514delC p. Gln172AsnfsX62
c.1687C>T p.Gln563Stop
c.3756_3759delGTCT p.Ser253ArgfsX10
c.5030_5033delCTAA p.Thr1677IlefsX2
185delAG 
5382insC 
BRCA2 c.514delC p.Gln172AsnfsX62
c.5796_5797delTA p.His1932GlnfsX12
c.6468_6469delTC p.Glu2157IlefsX18
6174delT 
6672insT 
6819delTG 
4075delGT 
R2034C 
G3076E 
10323delCins11 
IVS 16-2A>G (splice acceptor site of intron 16) 
IVS 15-1G>A (splice donor site of intron 15) 
M192T 
K3326X 
2458insT 
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Table A1 continued 
CDKN2A/p16 p.E27X
p.L65P
c.201 ACTC>CTTT (promoter)
p.G67R
p.R144C
p.G101W
p.E27X
-34G>T (initiation codon) 
c.47T>G p.L16R
c.71G>C p.R24P
c.192G>C L64L
c.238_251del p.R80fs
c.283del p.V95fs
c.318G>A p.V106V
c.457G>T D153spl (affects splicing)
c.324T>A p.V95E
c.482G>A p.A148T
c.323_324insG p.E119X
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Table A1 continued 
MEN1 c.304G>T p.R102S
c.723 to 724 del
320 CCC to C 
68 CCC to CC 
179 GAG to GTG 
c.249-252 del
c.183G>A p.W61X
c.196G>T p.V66F
c.482delG
c.1213C>T p.Q405X
c.969C>A p.Y323X
c.973G>C p.A325P
210-211insAGCCC 
c.712delA p.K201R
c.CCT>CCGG, p.55fs64aaX
c.GAG>AAG, p.E26K
c.AGC>AAAC p. 66fs50aaX
c. CGG>CAG p.R171Q
c.CTG>CCG p.L168P
c.GTG>GTTG p.236 fs12aaX
c.TAT>TAG p.T268X
c.GCC>CC p.437 fs15aaX
c.GCA>G p.510fs19aaX
c.CCG>GG p.493fs65aaX
MLH1 K618A 
MSH2 Q402X 
G322D 
E205Q 
V367I 
c.1046C>T p.P349L
c.1147C>T p.R383X
PALB2 c.1240C>T p.R414X
c.508-9delAG p.R170I,183X
c.3116delA, p.N1039fs
heterozygous 6.7kb deletion of exon 12 & 13 
c. 172-5delTTGT
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APPENDIX B: ABBREVIATIONS USED IN TEXT
CP= Chronic pancreatitis  
PC=Pancreatic cancer  
HP=Hereditary pancreatitis  
CP+PC= Documented chronic pancreatitis prior to pancreatic cancer  
CP-PC= Only chronic pancreatitis and no pancreatic cancer  
RR=Relative risk  
PDAC= Pancreatic ductal adenocarcinoma  
PanIN= Pancreatic intraepithelial neoplasia  
NER= Nucleotide excision repair  
NGS=Next generation sequencing  
SE= Single end read  
SD=Standard deviation  
NCBI GRCh37/hg19= National Center for Biotechnology Human Genome reference genome version 
GRCh37 /UCSC genome browser genome version hg19  
AN=coverage for a particular variant locus  
AC= coverage for non-reference allele at a particular variant locus  
AF= frequency of non-reference allele calculated as ratio of AC and AN converted as a percentage of 
100 
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